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ABSTRACT 
Gliomas are the most frequent pri-
mary brain tumours. The cardinal 
features of gliomas are infiltrative 
growth pattern and progression 
from low-grade tumours to a more 
malignant phenotype. These features 
of gliomas generally prevent their 
complete surgical excision and cause 
their inherent tendency to recur after 
initial treatment and lead to poor 
long-term prognosis. 
Increasing knowledge about the 
molecular biology of gliomas has 
produced new markers that supple-
ment histopathological diagnostics. 
Molecular markers are also used to 
evaluate the prognosis and predict 
therapeutic response. The purpose 
of this thesis is to study molecular 
events involved in the malignant 
progression of gliomas. 
Gliomas are highly vascularised 
tumours. Contrast enhancement in 
magnetic resonance imaging (MRI) 
reflects a disrupted blood-brain bar-
rier and is often seen in malignant 
gliomas. In this thesis, 62 astrocy-
tomas, oligodendrogliomas and oli-
goastrocytomas were studied by 
MRI and immunohistochemistry. 
Contrast enhancement in preopera-
tive MRI was associated with angio-
genesis, tumour cell proliferation 
and histological grade of gliomas. 
Activation of oncogenes by gene 
amplification is a common genetic 
aberration in gliomas. EGFR ampli-
fication on chromosome 7p12 oc-
curs in 30-40% of glioblastomas. 
PDGFRA, KIT and VEGFR2 are 
receptor tyrosine kinase genes lo-
cated on chromosome 4q12. Ampli-
fication of these genes was studied 
using in situ hybridisation in the 
primary and recurrent astrocytomas, 
oligodendrogliomas and oligoastro-
cytomas of 87 patients. PDGFRA, 
KIT or VEGFR2 amplification was 
found in 22% of primary tumours 
and 36% of recurrent tumours in-
cluding low-grade and malignant 
gliomas. The most frequent aberra-
tion was KIT amplification, which 
occurred in 10% of primary tumours 
and in 27% of recurrent tumours. 
The expression of ezrin, 
cyclooxygenase 2 (COX-2) and HuR 
was studied immunohistochemically 
in a series of primary and recurrent 
gliomas of 113 patients. Ezrin is a 
cell membrane-cytoskeleton linking-
protein involved in the migration of 
glioma cells. The COX-2 enzyme is 
implicated in the carcinogenesis of 
epithelial neoplasms and is overex-
pressed in gliomas. HuR is an RNA-
stabilising protein, which regulates 
the expression of several proteins 
including COX-2. Ezrin, COX-2 and 
HuR were associated with histologi-
cal grade and the overall survival of 
glioma patients. However, in multi-
variate analysis they were not inde-
pendent prognostic factors. 
In conclusion, these results sug-
gest that contrast enhancement in 
MRI can be used as a surrogate 
marker for the proliferative and an-
giogenic potential of gliomas. Aber-
rations of PDGFRA, KIT and 
VEGFR2 genes, as well as the dys-
regulated expression of ezrin, COX-
2 and HuR proteins, are linked to 
the progression of gliomas. 
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INTRODUCTION 
Gliomas are the most frequent pri-
mary brain tumours. They account 
for one third of all intracranial tu-
mours (Central Brain Tumor Regis-
try of the United States, 2011). 
Gliomas are neoplasms of the sup-
porting cells of the CNS (central 
nervous system). Their main sub-
types are astrocytomas, oligodendro-
gliomas, mixed oligoastrocytomas 
and ependymomas. The clinical be-
haviour of gliomas varies greatly 
from benign to extremely malignant. 
Half of the gliomas belong to the 
most malignant category, i.e. 
glioblastomas with a median survival 
time of 1 year.  
Infiltrating growth pattern and 
progression from a low-grade tu-
mour to a more malignant pheno-
type are characteristic of gliomas. 
These features generally prevent 
their complete surgical removal and 
curative treatment. Tumour recur-
rences are common and ultimately 
fatal to the patient. 
The histological transformation 
from low-grade neoplasia to secon-
dary malignant glioma and the ac-
cumulation of genetic alterations is 
best documented in astrocytomas 
but is also feature of oligodendro-
glial tumours. The two main types of 
genetic abnormalities involved in 
glioma progression are activation of 
oncogenes and inactivation of tu-
mour suppressor genes. Oncogenes 
promote cell proliferation and inva-
sion as well as inhibit apoptosis. In-
activation of tumour suppressor 
genes leads to impaired regulation of 
cell growth. 
Management of gliomas has pro-
gressed substantially during the past 
20 years. Advances in surgery, radia-
tion and chemotherapy have im-
proved the survival of glioma 
patients. Developments in neurora-
diology and neuropathology have 
refined the diagnostics of gliomas. 
Understanding of the molecular bi-
ology of brain tumours has increased 
rapidly. This knowledge has been 
assimilated into clinical neuropa-
thology to complete the histopa-
thological diagnosis. The molecular 
profiles of gliomas are also used in 
clinical neuro-oncology to the esti-
mate prognosis for patients (prog-
nostic markers) and to predict 
responses to chemotherapy or bio-
logical therapy (predictive markers). 
The objective of this thesis is to 
study molecular markers related to 
the progression and recurrence of 
low-grade gliomas. 
Review of the literature 
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REVIEW OF THE LITERATURE 
Pathobiology of glial cells 
The main cell types that comprise 
the CNS are neurons and neuroglial 
cells. Rudolf Virchow, in 1856, first 
described neuroglia as a connective 
substance where the nervous ele-
ments are embedded (Virchow, 1856 
cited in Somjen, 1988). Neurons are 
electrochemically active cells respon-
sible for nerve impulse conduction. 
The three types of neuroglial cells 
are astrocytes, oligodendrocytes and 
ependymal cells, together known as 
macroglial cells. They are supporting 
cells, which have important func-
tions in maintaining the homeostasis 
in the CNS. Neuroglial cells com-
prise approximately half of the total 
brain volume (Noback et al., 2005). 
Neurons and neuroglial cells are de-
velopmentally derived from neural 
tube ectoderm. The fourth type of 
supporting cells in the CNS is the 
microglial cells, which are brain 
equivalent for macrophages capable 
of obtaining antigen-presenting and 
phagocytic properties (Graeber and 
Streit, 2010). The name microglia is a 
misnomer, however. Microglial cells 
are not true neuroglial cells since 
they are of mesodermal origin. Pre-
cursor cells of microglia migrate to 
the brain parenchyma during early 
embryonic development (Monier et 
al., 2006). 
Astrocytes 
Astrocytes are the main supporting 
cells of the CNS; they constitute 20-
50% of brain volume depending on 
the anatomical region (Squire et al., 
2008). Astrocytes provide physical 
support for neurons and other cells 
of the CNS. Historically, the suppor-
tive properties of astrocytes were 
considered their main function. In 
recent years, however, their role in 
interactions with neurons and CNS 
function has been established 
(Sofroniew and Vinters, 2010). 
Astrocytes are further subclassi-
fied in fibrous and protoplasmic as-
trocytes on the basis of their 
morphology and anatomical distribu-
tion. Fibrous astrocytes with long 
processes are found in cerebral white 
matter. Protoplasmic astrocytes have 
extensively branching processes and 
are located in grey matter (Kiernan, 
1998). 
Processes of astrocytes ensheath 
synapses and even participate in syn-
aptic function through the release of 
regulating molecules called glio-
transmitters (Halassa et al., 2007). 
Astrocytic processes express trans-
port molecules that clear the synap-
tic space by facilitating the re-uptake 
of neurotransmitters such as gluta-
mate (Sofroniew and Vinters, 2010). 
Astrocytes maintain the fluid and ion 
homeostasis in the CNS through the 
aquaporin 4 water channel and K+ 
transporters (Seifert et al., 2006). 
Astrocytes have numerous contacts 
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with blood vessels and they are in-
volved in controlling the cerebral 
microcirculation (Iadecola and Ned-
ergaard, 2007). 
During the CNS development, 
the precursor cells of astrocytes are 
called radial glia, which give rise to 
astrocytes later in development 
(Vinters and Kleinschmidt-
DeMasters, 2008; Kriegstein and 
Alvarez-Buylla, 2009). Radial glia 
establish guiding fibers for neuro-
blasts when they migrate to the 
cerebral cortex. In fact, the radial glia 
are also progenitor cells which give 
rise to cortical pyramidal neurons as 
well (Kriegstein and Alvarez-Buylla, 
2009). 
Astrocytes have a crucial role in 
the reaction to any tissue damage in 
the CNS. Tissue injury, such as is-
chaemia, trauma, radiation injury, 
infection or neoplastic invasion, can 
evoke an astrocytic reaction termed 
gliosis, the CNS equivalent to scar-
ring elsewhere in the body. Astro-
cytic hypertrophy and proliferation 
are seen in both acute and chronic 
injuries to brain tissue. In a normal 
resting brain, the cytoplasm of astro-
cytes is barely visible in H&E stain-
ing. In reactive gliosis, the 
morphology of astrocytes is trans-
formed and astrocytes with abun-
dant cytoplasm, known as 
gemistocytic astrocytes, are formed. 
Astrocytic scarring may form 
borders along the region of tissue 
damage caused by ischaemia, infec-
tion or neoplasms. Glial scars are 
chronic and may exist in the brain 
tissue for a long period after the 
original insult has resolved (Sofro-
niew and Vinters, 2010). In clinical 
neuropathology, florid astrocytic 
gliosis is seen as a reaction to non-
glial brain neoplasms and metastases. 
Benign slowly growing gliomas such 
as pilocytic astrocytomas may evoke 
reactive gliosis in the tumour 
boundaries as well. 
Oligodendrocytes 
Oligodendrocytes are responsible for 
producing and maintaining the mye-
lin sheaths, which surround axons in 
the CNS (Kiernan, 1998). In the grey 
matter, oligodendrocytes are also 
clustered perineuronally as satellite 
cells. In the white matter, interfas-
cicular oligodendrocytes are arranged 
in rows along myelinated axons. Oli-
godendrocytes are smaller and have 
fewer processes than astrocytes. In 
H&E-stained paraffin sections the 
cytoplasm of oligodendrocytes is not 
visible, but instead an artefactual 
perinuclear halo is often present 
(Vinters and Kleinschmidt-
DeMasters, 2008). Oligodendrocytes 
share a common precursor cell with 
neurons and astrocytes. They are 
also derived from radial glia through 
intermediate progenitor cells (Krieg-
stein and Alvarez-Buylla, 2009). 
Oligodendrocyte responses to 
tissue injury are limited. They are 
vulnerable to oxidative damage, 
which contributes to oligodendro-
cyte loss in many disorders including 
multiple sclerosis and ischaemia 
(Bradl and Lassmann, 2010). In de-
myelinating diseases, such as multi-
ple sclerosis, oligodendrocyte 
proliferation can be seen as a repara-
tive response to injury (Vinters and 
Kleinschmidt-DeMasters, 2008). 
Review of the literature 
14 
Ependyma 
Ependymal cells line ventricular sur-
faces of the brain and the central 
canal of the spinal cord. Morpho-
logically ependymal cells share simi-
larities with columnar and cuboidal 
epithelial cells, but unlike epithelium, 
ependyma lacks basal lamina. The 
apical surface of ependymal cells is 
covered by microvilli and cilia (Del 
Bigio, 2010). Ependymal cells con-
tribute to fluid homeostasis between 
brain parenchyma and cerebrospinal 
fluid. 
Gliomas 
Origin of gliomas 
The origin of gliomas has excited 
neuropathologists and neuro-
oncologists for decades and is still 
enigmatic. The neoplastic transfor-
mation of mature glial cells has been 
introduced as an explanation for 
gliomagenesis. Since the first publi-
cation on the classification of glio-
mas by Bailey and Cushing (Bailey 
and Cushing, 1926 cited in Martin-
Villalba et al., 2008), the basis of 
classifications has been that the 
morphology of low-grade astrocy-
tomas resembles astrocytes and that 
oligodendrogliomas share common 
features with differentiated oli-
godendrocytes. Therefore, it seems 
reasonable that gliomas are derived 
from their mature counterpart cells. 
However, evidence supporting this 
hypothesis is lacking. The formation 
of gliomas through dedifferentiation 
of mature glial cells raises an inter-
esting question. Occasionally, glio-
mas contain several morphological 
components; e.g. oligoastrocytomas 
are composed of two types of glial 
cells and glioneuronal tumours con-
tain glial and neuronal cells. How are 
these gliomas formed if the cell of 
origin is a mature glial cell? 
Glial cell turnover in the adult 
brain is low. Glial cells, especially 
astrocytes, are able to proliferate as a 
response to injury after trauma or 
demyelination. The cells could ac-
quire mutations and other genetic 
changes when DNA duplicates in 
mitosis during reactive proliferation. 
However, epidemiological studies do 
not show convincing evidence of 
increased glioma incidence after 
trauma (Ohgaki and Kleihues, 
2005a). 
In diffuse gliomas, precursor le-
sions are not identified and thus, the 
first morphologically recognisable 
step in gliomagenesis is a low-grade 
neoplasm, e.g. grade II astrocytoma. 
In epithelial cancer such as colon 
carcinoma, the neoplastic lesion de-
velops in continuously dividing epi-
thelium. Furthermore, a continuum 
of the progression from a premalig-
nant adenoma to a malignant inva-
sive carcinoma can be identified in 
colon carcinoma (Fearon, 2010). In 
contrast to carcinomas, gliomas lack 
premalignant lesions equivalent to 
epithelial dysplasia; therefore, under-
standing of molecular events prior to 
low-grade glioma is still limited. 
The identification of neural stem 
cells and glial progenitor cells in 
adult brain has brought new per-
spectives to gliomagenesis. Neural 
stem cells are multipotent cells capa-
ble of generating multiple cell types 
and they are self-renewing; i.e. they 
can remain undifferentiated after cell 
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division (Yadirgi and Marino, 2009). 
Progenitor cells are precursors capa-
ble of producing cells that are of 
either neuronal or glial lineage, but 
not both (Sanai et al., 2005). The 
largest region containing neural stem 
cells in the human brain is the sub-
ventricular zone (SVZ) in the lateral 
wall of the lateral ventricle (Sanai et 
al., 2004). The SVZ contains a popu-
lation of astrocytes that behave as 
multipotent neural stem cells (Sanai 
et al., 2004). 
Glial progenitor cells have been 
identified in the human brain (Arm-
strong et al., 1992; Roy et al., 1999). 
During development, these glial pre-
cursors have three possible fates: 1) 
they can differentiate into mature 
glia, 2) they could die during early 
postnatal development or 3) a small 
subset remain immature and cycling 
through adult life (Canoll and 
Goldman, 2008). It has been esti-
mated that glial precursor cells ac-
count for up to 4% of adult white 
matter cells (Canoll and Goldman, 
2008). Hypothetically, if these pro-
genitor cells undergo transformation 
they could give rise to tumours that 
could differentiate into astrocytomas 
or oligodendrogliomas. In fact, the 
same signalling pathways that regu-
late self-renewal of normal stem cells 
are active in the transformation of 
tumour cells (Sanai et al., 2005). 
Tumour cells that are multipotent 
and capable of self-renewal are called 
cancer stem cells or tumour-
initiating cells (Jordan et al., 2006; 
Hadjipanayis and Van Meir, 2009). 
Cancer stem cells constitute only a 
small subpopulation of the tumour 
bulk but they are essential to tumour 
growth. Cancer stem cells show in-
creased resistance to radio- and 
chemotherapy. Therefore, it has 
been suggested that failure in cancer 
treatment reflects incomplete elimi-
nation of the cancer stem cells re-
sulting in the recurrence of tumours 
(Prestegarden and Enger, 2010). 
Tumour-initiating cells have been 
isolated from human gliomas and 
transplanted into mouse brains 
where they produce tumours that 
histologically mimic the original 
gliomas (Galli et al., 2004; Singh et 
al., 2004). 
Epidemiology 
Tumours of the CNS account for 
1.7% of all new cancers worldwide 
(Parkin et al., 2005). Gliomas repre-
sent 31% of the primary CNS tu-
mours (Central Brain Tumor 
Registry of the United States, 2011). 
In Finland, the incidence of gliomas 
was 4.7 per 100000 in a recent popu-
lation-based study (Larjavaara et al., 
2007). An increase in the incidence 
of gliomas during the 1970s and 
early 1980s has been reported in 
Finland (Kallio, 1993) and other 
Nordic countries (Lönn et al., 2004). 
This increase coincides with the in-
troduction of computed tomography 
(CT) into clinical practise and may 
reflect improved detection of glio-
mas (Lönn et al., 2004). 
The peak incidence of gliomas is 
between the ages of 45 and 70, 
which is mainly due to glioblas-
tomas, the most malignant type of 
gliomas (Louis et al., 2008). In chil-
dren, the benign pilocytic astrocy-
toma forms a lower incidence peak. 
Low-grade diffuse gliomas are most 
common in the 35-44 age group 
Review of the literature 
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(Okamoto et al., 2004; Central Brain 
Tumor Registry of the United States, 
2011). Males are more commonly 
affected; the male/female ratio of 
gliomas is 1.26 (Ohgaki and Klei-
hues, 2005b). 
Therapeutic high-dose radiation 
is the only environmental risk factor 
that is clearly associated with an in-
creased risk of gliomas. Children 
who have received prophylactic CNS 
irrradiation for acute lymphoblastic 
leukemia have an increased risk for 
developing brain tumors such as 
gliomas and primitive neuroecto-
dermal tumors (Ohgaki and Klei-
hues, 2005a). The rapid increase in 
mobile phone use during the last 20 
years has raised concerns about the 
possible link between radiofrequency 
electromagnetic radiation and brain 
tumors. A recent international case-
control study of mobile phone users 
concludes that they have no in-
creased risk for glioma or men-
ingioma (INTERPHONE Study 
Group, 2010). 
Several hereditary tumour syn-
dromes are characterised by predis-
position to gliomas among other 
tumours (Ohgaki and Kleihues, 
2005a). Neurofibromatosis 1 is asso-
ciated with pilocytic astrocytomas of 
the optic nerve and less frequently 
diffuse astrocytomas or glioblas-
tomas (Rodriguez et al., 2008). Neu-
rofibromatosis 2 patients have an 
increased risk for spinal ependymo-
mas. Patients with Li-Fraumeni syn-
drome carry germline mutations of 
the p53 gene and have increased 
incidence of astrocytic gliomas 
(Louis et al., 2007). 
Classification 
The first attempt at classification of 
gliomas on their histogenetic basis 
was made by Bailey and Cushing in 
1926 (Bailey and Cushing, 1926 cited 
in Martin-Villalba et al., 2008). Their 
classification showed that the histo-
pathology of the tumour is can give 
valuable information about the pa-
tient outcome. Predicting the behav-
iour of the tumour by means of 
histological grading is the principle 
of modern glioma classification as 
well. 
The World Health Organization 
(WHO) classification of gliomas ed-
ited by Zülch was first published in 
1979 (Zülch, 1979). The second edi-
tion, edited by Kleihues, appeared in 
1993 (Kleihues et al., 1993). In 1997, 
the International Agency for Re-
search of Cancer in collaboration 
with the International Society of 
Neuropathology, published a refer-
ence book that combined pathology 
and the genetics of brain tumours in 
one book (Kleihues and Cavenee, 
1997). Thereafter, the WHO classifi-
cation of brain tumours has included 
genetic alterations in the descriptions 
of tumour entities (Kleihues and 
Cavenee, 2000; Louis et al., 2007). 
The current WHO classification of 
gliomas published in 2007 is still 
based on the histopathological mor-
phology of the tumours (Louis et al., 
2007). 
Grading 
Histological grading of gliomas gives 
a powerful estimation of the biologi-
cal behaviour of the tumour and 
forms the basis for planning adju-
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vant therapies after surgical resec-
tion. 
WHO grade I is applied to tu-
mours, which are clearly circum-
scribed, benign in their behaviour 
and can be cured following total sur-
gical resection. WHO grade II tu-
mours are slowly progressing, low-
grade malignant tumours that exhibit 
cellular atypia without extensive pro-
liferation or anaplasia. Typical sur-
vival for grade II neoplasms is over 
5 years (Figure 1). WHO grade III 
tumours show increased cellularity, 
anaplasia and mitotic figures. Sur-
vival for grade III tumour is 2-3 
years. In grade IV tumours the histo-
logical hallmarks are necrosis and 
vascular proliferation in addition to 
grade III features. Together grade 
III-IV gliomas are called malignant 
gliomas. In a population-based 
study, the median survival for grade 
IV gliomas i.e. glioblastomas was 
less than 1 year (Ohgaki et al., 2004). 
In recent trials, there has been a 
promising tendency of improved 
prognosis when glioblastomas are 
treated with combined radiotherapy 
and chemotherapy (Glas et al., 2009; 
Stupp et al., 2009). Currently, there is 
considerable interobserver variability 
in the grading of gliomas, and new 
grading schemes are needed, in 
which histological criteria are un-
equivocally defined and scored 
(Kros, 2011). The main difference 
between grade I and grade II-IV 
gliomas is their growth pattern. Be-
nign grade I gliomas e.g. pilocytic 
astrocytomas are typically discrete 
while grade II-IV tumours show
Astrocytoma, grade II (n=43)
Anaplastic astrocytoma, grade III (n=20)
Glioblastoma, grade IV (n=15)
Figure  1  Survival of 78 patients with astrocytic gliomas WHO grade II-IV 
(study IV). 
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diffuse infiltration of neoplastic cells 
into the surrounding brain. The em-
phasis of this thesis is on diffuse 
gliomas, i.e. astrocytomas and oli-
godendrogliomas, grade II-IV. 
Histopathology of diffuse 
gliomas 
Diffuse astrocytoma 
The peak incidence of grade II dif-
fuse astrocytomas is between ages 30 
and 40. There is a slight male pre-
dominance 1.18:1 (Louis et al., 
2007). Cerebral hemispheres are 
mainly affected in adults. Brain stem 
and thalamus are more commonly 
affected in children. 
Diffuse astrocytomas WHO 
grade II show increased cellularity 
(2-3 times) compared to normal 
white matter. Due to their infiltrative 
nature, the margins of diffuse astro-
cytomas cannot be clearly defined. 
Neoplastic cells intermingle with 
normal structures and cells; they also 
follow axons and tracts. Astrocy-
toma cells infiltrate the cortex and 
deep gray matter and surround neu-
rons (perineuronal satellitosis). Mi-
crocystic change of tumour tissue is 
a common feature. 
The two main histological sub-
types are fibrillary and gemistocytic 
astrocytoma. In fibrillary astrocy-
toma, tumour cells have scant cyto-
plasm with numerous processes 
forming a fibrillary background. Nu-
clei are enlarged, hyperchromatic 
and irregular in shape. Gemistocytic 
astrocytomas are characterised by 
the plump eosinophilic cytoplasm 
and eccentric nuclei of the neoplastic 
cells. The rare variant protoplasmic 
astrocytoma consists of small cells 
with few cytoplasmic processes and 
mucoid or microcystic matrix. Some 
studies suggest that gemistocytic 
morphology is an unfavourable 
prognostic feature in astrocytomas 
(Shaw et al., 1989; Krouwer et al., 
1991; Okamoto et al., 2004). Gemis-
tocytic astrocytomas are prone to 
undergo malignant progression more 
rapidly than fibrillary astrocytomas 
(Louis et al., 2007). 
There is no strict cut-off value 
for mitotic figures in grade II astro-
cytomas but generally occasional 
mitoses are accepted especially in 
large tumour samples. However, in 
small stereotactic biopsies, even sin-
gle mitotic figure may allow grading 
to anaplastic astrocytoma if other 
cellular features are consistent with 
anaplasia. 
Anaplastic astrocytoma 
Anaplastic astrocytomas share the 
main histopathological features with 
diffuse astrocytomas with signs of 
focal or diffuse anaplasia. Anaplastic 
astrocytomas are hypercellular with 
marked mitotic activity and nuclear 
pleomorphism. The shape of nuclei 
is more angular and chromatin struc-
ture coarse compared to grade II 
astrocytomas. Anaplastic astrocy-
tomas occur in the older age group 
compared to the grade II astrocy-
tomas. Their peak incidence is ap-
proximately 45 years (Louis et al., 
2007). 
Glioblastoma 
Glioblastomas are the most com-
mon primary brain tumours. They 
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account for 12-15% of all intracra-
nial neoplasms (Louis et al., 2007). 
Glioblastomas occur preferentially in 
adults; their peak incidence is be-
tween 40 and 70 years. 
Glioblastomas are the most ma-
lignant gliomas. The morphology of 
glioblastomas may be extremely het-
erogeneous as indicated in their pre-
vious name glioblastoma multi-
forme. Both cellular and nuclear 
pleomorphism is a prominent fea-
ture. Mitotic figures and atypical mi-
toses are frequent. Cellular 
composition varies from small fusi-
form cells to multinucleated giant 
cells. 
The key features distinguishing 
glioblastomas from lower-grade as-
trocytomas are necrosis and mi-
crovascular proliferation. Typically, 
glioblastomas have large central ne-
croses surrounded by vital tumour 
tissue as seen in MRI imaging. The 
histologically characteristic form of 
necrosis consists of irregular necrotic 
foci surrounded by a radially ori-
ented pseudopalisading zone of 
glioma cells. Thrombosed vessels are 
frequently seen in necrotic tumour 
areas. Brat et al. have postulated that 
glioma cells form pseudopalisades 
when migrating away from the hy-
poxic focus, which is often caused 
by vessel thrombosis (Brat et al., 
2004). 
Microvascular proliferation ap-
pears as glomeruloid vascular struc-
tures, which consist of hyperplastic 
endothelial and smooth muscle cells 
(Wesseling et al., 1995). Glomeruloid 
vessels are often seen near necrotic 
foci and less frequently at the infil-
trating edge of glioblastomas. 
Glioblastomas are divided into 
two subtypes that are histologically 
indistinguishable. Primary glioblas-
tomas (de novo glioblastomas) de-
velop without a previous clinical 
history of glioma. Secondary 
glioblastomas arise through malig-
nant progression from pre-existing 
lower-grade astrocytomas (Louis et 
al., 2007). 
The vast majority (over 90%) of 
glioblastomas are primary. They usu-
ally develop at old age (mean 62 
years) with short clinical history of 
symptoms (mean 6 months) (Ohgaki 
et al., 2004; Ohgaki and Kleihues, 
2005b). Secondary glioblastomas are 
rare tumours comprising less than 
10% of all glioblastomas. They de-
velop at younger age (mean 45 years) 
and more frequently in women 
(male/female ratio 0.65) (Ohgaki 
and Kleihues, 2005b). Progression 
from grade II glioma to glioblastoma 
takes an average for 5.3 years and 
from grade III glioma for 1.4 years 
(Ohgaki and Kleihues, 2005b). Ap-
proximately 70% of grade II gliomas 
progress into grade III/IV (Furnari 
et al., 2007). 
Several morphological variants of 
glioblastoma are recognised. Occa-
sionally glioblastomas contain oli-
godendroglioma-like areas. Ac-
cording to the WHO 2007 classi-
fication, these tumours should be 
called glioblastomas with oligodendroglial 
component, and they may have better 
prognosis than ordinary glioblas-
tomas (Louis et al., 2007). Small cell 
glioblastomas are composed of a dense 
infiltrate of small monomorphic tu-
mour cells with round or slightly 
elongated nuclei. These tumours 
should be distinguished from poorly 
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differentiated anaplastic oligoden-
drogliomas. Gliosarcoma is a biphasic 
variant of glioblastoma consisting of 
a malignant glial and sarcomatous 
mesenchymal component. Giant cell 
glioblastoma consists of bizarre, multi-
nucleated giant cells. This variant 
may exhibit a less infiltrative growth 
pattern and slightly favourable prog-
nosis (Louis et al., 2007). 
Oligodendroglioma 
Oligodendrogliomas account for 5% 
of all gliomas Oligodendrogliomas 
arise primarily in the cerebral hemi-
spheres of adults with a peak inci-
dence between 40 and 45 years of 
age (Louis et al., 2007). In children, 
oligodendroglioma is rare. The car-
dinal histological features of oli-
godendrogliomas are round nuclei 
and perinuclear halo artefact in par-
affin sections, producing a typical 
morphology resembling fried egg. 
Oligodendrogliomas typically infil-
trate to cerebral cortex where neo-
plastic cells gather around neurons 
(perineuronal satellitosis). Migrating 
tumour cells often accumulate at the 
subpial surface of the cortex. These 
growth patterns are called secondary 
structures of Scherer (Scherer, 1938 
cited in Claes et al., 2007). Micro-
cysts and calcifications are also fea-
tures of oligodendrogliomas, al-
though they are non-specific. 
Occasionally oligodendrogliomas 
contain minigemistocytes resembling 
gemistocytic astrocytes. Reactive 
astrocytes are usually scattered 
evenly throughout the oligodendro-
glioma. The branching capillary net-
work of oligodendrogliomas resem-
bles chicken wire pattern. Occasional 
mitoses are compatible with the di-
agnosis of grade II oligodendro-
glioma (Louis et al., 2007). 
Anaplastic oligodendroglioma 
Anaplastic oligodendrogliomas ac-
count for 1.3% of gliomas. They 
manifest in the slightly older age 
group compared to low-grade oli-
godendrogliomas, with a peak inci-
dence between 45 and 50 years 
(Louis et al., 2007). 
Morphologically anaplastic oli-
godendrogliomas show high cellular-
ity. There is marked nuclear atypia 
and mitotic figures are frequent. In 
addition to characteristic branching 
capillaries of oligodendrogliomas, 
microvascular proliferation may be 
present. Foci of necrosis are present 
in one third of anaplastic oligoden-
drogliomas (Miller et al., 2006). 
Oligoastrocytoma and 
anaplastic oligoastrocytoma 
Oligoastrocytomas are defined as 
tumours with two cell components 
resembling astrocytoma and oli-
godendroglioma. The two cellular 
components are usually intermin-
gled. In rare cases, the tumour is 
biphasic and can be divided into as-
trocytic and oligodendrocytic areas. 
Currently, there is considerable in-
terobserver variability in the diagnos-
tics of oligoastrocytic tumours due 
to lack of definite histological criteria 
(Kros et al., 2007). 
Grade II oligoastrocytomas show 
moderate cellularity and low mitotic 
activity. Microcystic change and cal-
cification may be present. In 
anaplastic oligoastrocytomas, diag-
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nostic features are high cellularity, 
obvious mitotic activity, cellular 
pleomorphism and microvascular 
proliferation. Anaplastic oligoastro-
cytomas with necrosis should be 
classified as glioblastomas with an 
oligodendroglial component, be-
cause necrosis is marker of poor 
prognosis in these tumours (Miller et 
al., 2006; Louis et al., 2007). 
Histological types and survival 
Median survival times by histological 
glioma type from population-based 
studies are shown in Table 1. Oli-
godendroglial tumours generally 
have a better prognosis than astrocy-
tomas of the corresponding WHO 
grade. Clinical trials usually show 
better outcomes than population-
based studies due to bias towards 
recruitment of younger patients and 
patients with better performance 
status (Louis et al., 2007). The 
glioblastoma patients presented in 
Table 1 were diagnosed and treated 
before the era of modern chemora-
diotherapy (see later). 
Molecular pathogenesis 
of gliomas 
Natural course of diffuse 
gliomas 
Recurrence after treatment and pro-
gression towards a more malignant 
phenotype are inherent characteris-
tics of diffuse gliomas. Most low-
grade gliomas develop a recurrent 
tumour after variable periods of 
time. Often the recurrent tumour 
shows histologically increased cellu-
larity, nuclear atypia and mitoses as 
features of morphological progres-
sion (Figure 2). Molecular patho-
genesis of gliomas is a stepwise 
process where genetic alterations 
accumulate in glial cells causing ini-
tiation and progression of the tu-
mour. Therefore, the number of 
genetic changes is greatest in 
glioblastomas. Single molecular 
events can be dated to certain steps 
of tumour evolution and correlated 
with histological phenotype. The 
path of progression at both the his-
tological and molecular level has 
Table  1 Mean age and median survival of gliomas in a population-based 
material from Switzerland, diagnosed in 1980-1994. 
Tumour histology
WHO 
grade n
Mean 
age
Median survival 
(years)
Astrocytoma II 52 41.0 5.6
Oligoastrocytoma II 20 41.1 6.6
Oligodendroglioma II 50 40.9 11.6
Anaplastic astrocytoma III 47 45.5 1.6
Anaplastic oligoastrocytoma III 11 48.2 –
Anaplastic oligodendroglioma III 13 50.4 3.5
Glioblastoma IV 680 62.2 0.4
Source: (Okamoto et al., 2004; Ohgaki and Kleihues, 2005b).  
Review of the literature 
22 
been best characterised in astrocy-
tomas. Hanahan and Weinberg have 
suggested that cancer cells share six 
critical alterations, the hallmarks of 
cancer, that enable their malignant 
behaviour: 1) self-sufficiency in 
growth signals, 2) insensitivity to 
growth-inhibiting signals, 3) resis-
tance to apoptosis, 4) limitless repli-
cation, 5) angiogenesis and 6) tissue 
invasion and metastasis (Hanahan 
and Weinberg, 2000). In their recent 
review, the authors have updated the 
cancer hallmarks and added two 
emerging characteristics of cancer 
cells: 1) metabolic reprogramming 
(aerobic glycolysis) and 2) capability 
of avoiding destruction by the im-
mune system (Hanahan and 
Weinberg, 2011). Most of these 
characteristics are common for dif-
ferent types of cancers including 
gliomas and will be reviewed in the 
following sections. 
Oncogenes 
EGFR 
Oncogenes are altered genes that 
promote the neoplastic transforma-
 
Figure  2  Histological progression of gliomas. A, low-grade astrocytoma show-
ing low cellularity and nuclear atypia. B, 5 years later the tumour in 
fig. A has progressed to glioblastoma with high cellularity, vascular 
proliferation and necrosis. C, low-grade oligodendroglioma shows 
round nuclei and prinuclear halos. D, recurrence of the tumour in fig. 
C 10.5 years later with increased cellularity and vascular proliferation. 
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tion of cells. Activation of onco-
genes occurs by mutation or amplifi-
cation of their normal cellular 
counterparts proto-oncogenes. 
Epidermal growth factor receptor 
(EGFR) is the most frequently am-
plified gene in glioblastomas. EGFR 
is a member of the ErbB family of 
tyrosine kinase receptors, which are 
often dysregulated in cancer. EGFR 
amplification and overexpression are 
reported in over 30% of all glioblas-
tomas (including primary and secon-
dary) (Louis, 2006). The EGFR gene 
is located at chromosome 7p12. It 
encodes a 170 kD transmembrane 
tyrosine kinase receptor protein. 
EGF and TGF-α are ligands for the 
EGFR. Activation of wild-type 
EGFR by its ligand triggers signal-
ling cascade, which enhances cell 
proliferation and migration (Yarden 
and Sliwkowski, 2001). Amplifica-
tion of the EGFR gene leads to 
overexpression at the mRNA and 
protein level and is often associated 
with structural alterations of the 
gene. Amplified EGFR genes are 
usually extrachromosomal double 
minute fragments. EGFR amplifica-
tion is typical genetic alteration in 
primary glioblastomas, present in ca. 
40% of cases (Ohgaki and Kleihues, 
2007). In secondary glioblastomas, 
EGFR amplification is rare (Ohgaki 
et al., 2004). 
The most common mutant of 
EGFR gene is EGFRvIII, which 
occurs in 50-60% of tumours with 
EGFR amplification (Furnari et al., 
2007). The mutant EGFRvIII results 
from deletions of exons 2-7 and lead 
to truncated form of EGFR protein 
lacking part of extracellular domain. 
EGFRvIII is constitutively active 
resulting in increased proliferation 
and reduced apoptosis (Furnari et al., 
2007). 
KIT, PDGFRA and VEGFR2 
KIT, PDGFRA and VEGFR2 
(KDR) are receptor tyrosine kinase 
genes that are clustered on chromo-
somal segment 4q12. Under physio-
logical conditions, KIT is activated 
by the binding of its ligand stem cell 
factor (Antonescu, 2011). Activation 
of KIT triggers signalling cascades 
that result in cell proliferation and 
inhibition of apoptosis (Kitamura 
and Hirotab, 2004). Oncogenic mu-
tations of KIT are found in the ma-
jority of gastrointestinal stromal 
tumours (Hirota et al., 1998) as well 
as in a subset of melanomas (Curtin 
et al., 2006) and seminomas (Tian et 
al., 1999) but they are uncommon in 
other types of solid cancer (Sihto et 
al., 2005). High-level KIT amplifica-
tion is present in 33% of glioblas-
tomas but its overexpression at 
protein level is rare (Joensuu et al., 
2005). 
PDGFRA and its ligand PDGF 
are overexpressed in malignant 
gliomas (Fleming et al., 1992; Guha 
et al., 1995; Lokker et al., 2002; 
Joensuu et al., 2005; Paulsson et al., 
2011), which suggests the presence 
of an autocrine signalling loop. Am-
plification of the PDGFRA gene has 
been found in a subset of glioblas-
tomas (Fleming et al., 1992; Her-
manson et al., 1996; Joensuu et al., 
2005; Verhaak et al., 2010). In an 
experimental cell culture and mouse 
model, overexpression of PDGF in 
neural progenitor cells by gene trans-
fer has been shown to induce tu-
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mours identical to human oligoden-
drogliomas (Dai et al., 2001). 
VEGFR2 is predominantly ex-
pressed in endothelial cells of 
glioblastomas but may be present in 
tumour cells as well (Hatva et al., 
1995; Steiner et al., 2004). The 
VEGFR2 gene is amplified in 22% 
of glioblastomas (Joensuu et al., 
2005). KIT, PDGFRA, and 
VEGFR2 genes are concurrently 
amplified in up to 21% glioblas-
tomas (Joensuu et al., 2005). The 
role of PDGFRA and VEGFR2 in 
the angiogenesis of gliomas will be 
discussed later. 
Tumour suppressor genes 
p53 
Tumour suppressor genes are 
growth-controlling genes of the cells. 
Their inactivation by deletions, mu-
tations or epigenetic mechanisms 
leads to dysregulation of the cell cy-
cle and is a common mechanism in 
the development of cancer. 
p53 is a tumour suppressor gene 
located at chromosome 17p13. Inac-
tivation of p53 by mutations leads to 
the accumulation of non-functioning 
protein in the cell. Dysfunction of 
the p53 pathway is one of the most 
common molecular alterations in 
human malignancies. Intact p53 re-
sponds to DNA damage or onco-
gene activation by blocking the cell 
cycle in the G1 phase or by inducing 
apoptosis, preventing possible neo-
plastic transformation of the cell 
(Furnari et al., 2007). The p53 muta-
tion is a hallmark of diffuse astrocy-
tomas (Louis et al., 2007). p53 
mutation is an early event in the 
progression of astrocytomas (Figure 
3); over half of grade II astrocy-
tomas carry the p53 mutation (Wa-
tanabe et al., 1997; Okamoto et al., 
2004). Therefore, the p53 mutation 
is frequent in secondary glioblas-
tomas, which develop from lower-
grade gliomas (Ohgaki and Kleihues, 
2007). p53 protein accumulation is 
frequent in astrocytomas, but ele-
vated protein expression is not al-
ways due to mutation. Immuno-
histochemical p53 staining is useful 
in differentiating between astrocy-
tomas and oligodendrogliomas in 
neuropathological diagnostics. 
Strong nuclear staining for p53 often 
reflects mutation of the gene and is 
more frequent in astrocytomas than 
in oligodendrogliomas (Gupta et al., 
2005). Mutations of the p53 gene 
can be heterogeneous, and one 
glioma may contain tumour cells 
with different p53 mutations (Ren et 
al., 2007). 
PTEN and Rb1 
The PTEN gene, located at 10q23.3, 
is a tumour suppressor gene that is 
inactivated by deletion or mutation 
in up to 40% of glioblastomas 
(Knobbe et al., 2002; Cancer Ge-
nome Atlas Research Network, 
2008). PTEN is part of the 
PI3K/PTEN/AKT pathway, and its 
inactivation eventually leads to cell 
proliferation (Knobbe et al., 2002). 
The retinoblastoma gene (Rb1) 
encodes Rb protein that regulates 
transition from G1 phase to S phase 
in the cell cycle (Harbour and Dean, 
2000). Rb1 is inactivated by deletion 
in one third of high-grade astrocy-
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tomas (Henson et al., 1994; Ichimura 
et al., 1996). 
1p and 19q deletions 
Deletions of chromosome arms 1p 
and 19q are characteristic of oli-
godendroglial tumours (von Deim-
ling et al., 1992; Reifenberger et al., 
1994; Cairncross et al., 1998). Co-
deletion of 1p and 19q is present in 
44-80% of oligodendrogliomas 
(Smith et al., 2000; Watanabe et al., 
2002; Okamoto et al., 2004; Jeuken 
et al., 2010) and in 20-30% of oli-
goastrocytomas (Smith et al., 2000; 
Jeuken et al., 2001; Jeuken et al., 
2010). 1p/19q deletion frequently 
involves the chromosome arms in 
their entirety. Loss of heterozygosity 
(LOH) of 1p and 19q is mediated by 
unbalanced translocation 
t(1;19)(q10;p10), where derivative 
chromosome 1p-19q is lost (Griffin 
et al., 2006; Jenkins et al., 2006). So 
 
Figure  3  Summary of the most frequent genetic alterations during the pro-
gression of gliomas (Louis et al., 2007; Riemenschneider et al., 
2010). 
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far, the search for tumour suppres-
sor genes in these chromosome arms 
has been unsuccessful (Jansen et al., 
2010). 
Oligodendrogliomas that have 
classic histological features such as 
uniform round nuclei with perinu-
clear halo and a vascular pattern re-
sembling chicken wire show strong 
correlation with 1p/19 co-deletion 
(Giannini et al., 2008; Scheie et al., 
2008). 
1p/19q deletion is a powerful 
prognostic and predictive marker for 
oligodendroglial tumours. Loss of 
1p/19q was reported to associate 
with better response to chemother-
apy and longer overall survival in 
anaplastic oligodendrogliomas in 
1998 (Cairncross et al., 1998). The 
prognostic value of 1p/19q loss in 
anaplastic oligodendrogliomas and 
oligoastrocytomas has been con-
firmed in clinical trials (Cairncross et 
al., 2006; van den Bent et al., 2006). 
Deletion of 1p/19q predicts a che-
motherapy response and better 
overall survival in low-grade gliomas 
as well (Kaloshi et al., 2007). How-
ever, the effect of 1p/19q deletion 
on patient outcome may be smaller 
in low-grade gliomas and its role in 
the management of patients is still 
controversial (Jansen et al., 2010; 
Tabatabai et al., 2010). 
Loss of 1p/19q seems to have 
prognostic importance only in pa-
tients treated with either radiother-
apy or combined radiotherapy and 
chemotherapy. 1p/19q loss was not 
prognostic marker for progression-
free survival in patients who under-
went surgical resection for their oli-
godendroglial tumour without 
further treatment (Weller et al., 
2007). 
MGMT 
MGMT (O6 methylguanine-DNA 
methyltransferase) is an enzyme that 
repairs DNA damage caused by alky-
lating chemotherapeutic agents used 
in the treatment of gliomas (Esteller 
et al., 2000). Therefore, functioning 
MGMT enzyme causes resistance to 
alkylating drugs such as temo-
zolomide. The MGMT gene is lo-
cated at chromosome 10q26. Its 
transcription is inactivated by methy-
lation of CpG islands in the gene 
promoter area in several human can-
cers including gliomas (Esteller et al., 
1999). MGMT gene is methylated in 
41-45% of glioblastomas (Esteller et 
al., 1999; Hegi et al., 2005). 
MGMT promoter methylation is 
associated with a response to temo-
zolomide treatment in glioblastoma 
patients and has therefore been in-
troduced as a predictive marker for 
chemotherapy (Hegi et al., 2005). 
However, MGMT methylation is a 
favourable marker for survival even 
in glioblastoma patients who have 
received radiation treatment, but not 
chemotherapy (Rivera et al., 2010). 
Thus, MGMT methylation may not 
be just a positive predictive marker 
for chemotherapy, but indicates in 
general a favourable prognostic phe-
notype in glioblastoma (Jansen et al., 
2010). MGMT methylation is corre-
lated with 1p/19q deletion and 
prognosis in anaplastic oligodendro-
gliomas as well (van den Bent et al., 
2009). 
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IDH1 
The IDH1 gene in chromosome 
2q33 encodes cytoplasmic isocitrate 
dehydrogenase-1 enzyme, which 
participates in the citric acid cycle. 
Mutations of the IDH1 gene are a 
novel finding in gliomas. IDH1 gene 
mutations were reported in 12% of 
22 glioblastomas in a comprehensive 
genomic analysis of over 20000 pro-
tein-coding genes. In this genome-
wide analysis, the investigators 
searched for mutations in genes that 
were previously not known to be 
altered in glioblastomas (Parsons et 
al., 2008). In a larger series of 321 
gliomas, IDH1 was frequently mu-
tated in low-grade astrocytomas 
(88%) and oligodendrogliomas 
(79%) (Watanabe et al., 2009). IDH2 
is a mitochondrial counterpart of 
IDH1, and it is less frequently mu-
tated in gliomas. Three percent of 
diffuse gliomas carry the IDH2 mu-
tation (Hartmann et al., 2009). 
IDH1 mutation is a very early 
event in gliomagenesis (Figure 3). In 
multiple biopsies of gliomas, IDH1 
mutation is present before p53 mu-
tations or 1p/19q loss (Watanabe et 
al., 2009). This suggests that IDH1 
mutation takes place in glial precur-
sor cells, and subsequent acquisition 
of the p53 mutation may lead to as-
trocytic differentiation while loss of 
1p/19q leads to an oligodendrocytic 
phenotype (Watanabe et al., 2009). 
IDH1 mutation is present in 82% of 
secondary glioblastomas and rarely 
in primary glioblastomas (5%) sug-
gesting different origins of these 
glioblastoma subtypes (Watanabe et 
al., 2009). 
IDH1 mutation is a favourable 
prognostic factor in all grades of 
diffuse gliomas (Dubbink et al., 
2009; Sanson et al., 2009; Weller et 
al., 2009; Wick et al., 2009; van den 
Bent et al., 2010). Furthermore, 
anaplastic astrocytomas without the 
IDH1 mutation have an even worse 
outcome than glioblastomas with 
mutated IDH1 (Hartmann et al., 
2010). IDH1 mutation is also associ-
ated with 1p/19q co-deletion and 
MGMT promoter methylation in 
gliomas (Sanson et al., 2009; La-
bussiere et al., 2010; van den Bent et 
al., 2010). 
Mutations of the IDH1 and 
IDH2 genes can be detected by 
DNA sequencing (Parsons et al., 
2008). Over 90% of IDH1 muta-
tions result in substitution the of 
amino acid arginine by histidine at 
codon 132 (p.R132H) (Hartmann et 
al., 2009). Monoclonal antibodies 
against mutant p.R132H IDH1 pro-
tein have been recently developed 
(Capper et al., 2009; Kato et al., 
2009). These antibodies are suitable 
for paraffin-embedded tissues and 
allow inexpensive immunohisto-
chemical detection of the most 
common IDH1 mutation in routine 
clinical neuropathology. 
Currently, there are different hy-
potheses on the oncogenic mecha-
nism of IDH1 mutations. The 
heterozygous mutation of IDH1 
leads to reduced formation of its 
product α-ketoglutarate, which in-
creases the levels of HIF-1α in cul-
tured glioblastoma cells (Zhao et al., 
2009). HIF-1 is a transcription factor 
that regulates genes implicated in 
tumour angiogenesis and cell prolif-
eration (Semenza, 2010). These re-
sults suggest that IDH1 could act as 
a tumour suppressor gene (Zhao et 
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al., 2009). However, the direct rela-
tionship between IDH1 mutation 
and HIF-1α upregulation has been 
questioned. Williams and co-workers 
analysed 120 gliomas by IDH1 and 
HIF-1α immunohistochemistry (Wil-
liams et al., 2011). In their publica-
tion, the link between the expression 
of mutant IDH1 and HIF-1α was 
not evident, suggesting that activa-
tion of the HIF-1α pathway is not 
primarily regulated by IDH1 muta-
tion. 
Another mechanism for IDH1-
related tumourigenesis has been sug-
gested by Dang et al. They have 
shown that mutated IDH1 gains a 
novel enzymatic activity and is able 
convert α-ketoglutarate to 2-
hydroxyglutarate (2HG) (Dang et al., 
2009). Accumulation of 2HG could 
be a tumourigenic event in the brain, 
suggesting an oncogenic gain of 
function of mutated IDH1 (Jansen 
et al., 2010). 
Markers of tumour cell 
differentiation and phenotype 
Intermediate filaments 
Identification of the origin and dif-
ferentiation of tumour cells by 
studying their protein expression is a 
basic method in modern pathology. 
Immunohistochemistry is used to 
investigate cytoplasmic, nuclear and 
membranotic antigens in the classifi-
cation of tumours. 
Intermediate filaments (IF) are 
constituents of the cell cytoskeleton. 
The IF proteins are subclassified by 
their sequence homology into six 
classes: I-II) cytokeratins, III) 
vimentin, desmin and glial fibrillary 
acidic protein (GFAP), IV) neuro-
filament proteins and α-internexin, 
V) nuclear proteins lamins, VI) 
nestin (Dahlstrand et al., 1992; 
Herrmann and Aebi, 2000). 
GFAP is expressed in normal, re-
active and neoplastic astrocytic cells. 
GFAP immunohistochemistry is a 
useful tool in clinical neuropathology 
differentiating glial tumours from 
meningeal neoplasms and metasta-
ses. Although GFAP expression 
tends to decrease during the course 
of glioma progression (Louis et al., 
2008), focal GFAP reactivity is usu-
ally still seen even in poorly differen-
tiated glioblastomas. GFAP 
expression is found in 80% of oli-
godendroglial tumours; therefore, its 
use in differentiating oligodendro-
gliomas from astrocytomas is limited 
(Ikota et al., 2006). In oligodendro-
gliomas, expression of α-internexin 
associates with 1p/19q deletions 
(Ducray et al., 2009) and the proneu-
ral gene expression profile, which is 
related to good prognosis (Ducray et 
al., 2008). 
Vimentin is expressed in both as-
trocytic and oligodendroglial tu-
mours (Dehghani et al., 1998; 
Koperek et al., 2004; Ikota et al., 
2006). Nestin is a class VI intermedi-
ate filament that is expressed in neu-
ral stem cells and in high-grade 
astrocytomas and oligodendroglio-
mas (Lendahl et al., 1990; Dahl-
strand et al., 1992; Ikota et al., 2006). 
Poorly differentiated and metaplastic 
glioblastomas rarely express cy-
tokeratins (Oh and Prayson, 1999). 
Therefore, cytokeratin immunohis-
tochemistry combined with GFAP 
can be used in differentiating glio-
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mas from metastatic carcinomas. 
Cytokeratin antibody CAM 5.2 is 
useful in this setting. However, cy-
tokeratin antibody AE1/AE3 should 
be avoided because it is frequently 
positive in glioblastomas, probably 
due to non-specific cross-reactivity 
with other intermediate filaments 
(Oh and Prayson, 1999). 
 
Other markers of differentiation 
OLIG2 is a recently identified tran-
scription factor that regulates oli-
godendroglial development (Yokoo 
et al., 2004). OLIG2 expression is 
high in diffuse gliomas but is also 
found in other primary CNS malig-
nancies (Ligon et al., 2004). Immu-
nohistochemical OLIG2 staining can 
be used in differentiating between 
primary CNS tumours and metasta-
sis (Ligon et al., 2004). 
Histological classification of 
gliomas includes specific entities of 
mixed glioneuronal tumours. How-
ever, neuronal differentiation at the 
molecular level is present in a subset 
of diffuse gliomas even without his-
tological features of neuronal mor-
phology. Neurofilament expression 
has been found immunohistochemi-
cally in astrocytomas and in oli-
godendrogliomas (Wharton et al., 
1998; Wharton et al., 2002). Other 
neuronal antigens such as synapto-
physin, neuronal nuclear antigen 
(NeuN) and chromogranin are ex-
pressed in glioblastomas, especially 
in the giant cell subtype (Donev et 
al., 2010).  
Molecules linked to glioma 
progression 
Actin and ERM proteins 
Actin microfilaments are a major 
constituent of the cell cytoskeleton. 
Actin has a key role in cell motility 
and migration. In brain physiology, 
actin cytoskeleton is involved in 
axon formation of neurons. Actin 
filaments are in closely involved with 
the cell membrane. Important me-
diators of this interaction are the 
members of the ERM (ezrin-radixin-
moesin) protein family (Tsukita and 
Yonemura, 1997; Vaheri et al., 
1997).  
Astrocytes are capable of migrat-
ing to the site of tissue damage in 
the CNS. Ezrin and radixin are local-
ised in peripheral astrocytic proc-
esses in rat cell cultures suggesting 
their possible role in astrocyte motil-
ity (Derouiche and Frotscher, 2001). 
Ezrin expression has been con-
firmed immunohistochemically in 
human astrocytes as well (Geiger et 
al., 2000; Grönholm et al., 2005). 
Ezrin has been implicated in the 
progression of several human can-
cers. Ezrin participates in motility 
and invasion of pancreatic cancer 
cells (Meng et al., 2010) as well as in 
osteosarcoma metastasis (Khanna et 
al., 2004). Furthermore, ezrin ex-
pression is associated with the inva-
sion of cutaneous melanoma 
(Ilmonen et al., 2005). Ezrin is an 
unfavourable prognostic factor in 
uveal melanoma and colorectal car-
cinoma (Mäkitie et al., 2001; El-
zagheid et al., 2008). 
In neuroepithelial tumours, ezrin 
expression has been detected in as-
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trocytomas (Geiger et al., 2000), 
ependymomas (Böhling et al., 1996; 
Snuderl et al., 2008), gangliogliomas 
(Majores et al., 2005) and medul-
loblastomas (Osawa et al., 2009). 
Overexpression of ezrin is correlated 
with increasing malignancy grade in 
astrocytomas (Geiger et al., 2000). In 
medulloblastomas, ezrin promotes 
tumour cell invasion (Osawa et al., 
2009). Merlin (schwannomin), an-
other member of the moesin-ezrin-
radixin (i.e. ERM) family is the tu-
mour suppressor gene involved in 
neurofibromatosis 2 syndrome (Ast-
hagiri et al., 2009). 
COX-2 
Cyclooxygenase (COX) is the key 
enzyme in prostaglandin synthesis. 
The two isoforms COX-1 and 
COX-2 catalyze the conversion of 
arachidonic acid to prostaglandins 
(Dubois et al., 1998). COX-1 is con-
stitutively expressed in several tis-
sues including brain (Menter et al., 
2010). COX-2 is an inducible en-
zyme, which is normally not ex-
pressed in most tissues, but is 
upregulated in inflammation (Wang 
and Dubois, 2010a). 
COX-2 has been implicated in 
carcinogenesis and it is dysregulated 
in many cancers such as carcinomas 
of the colon (Eberhart et al., 1994), 
stomach (Ristimäki et al., 1997) and 
breast (Hwang et al., 1998). Epide-
miological studies have indicated 
that prolonged use of non-steroidal 
anti-inflammatory drugs (NSAID) 
reduces the risk of developing colo-
rectal cancer (Thun et al., 2002). It 
has been hypothesized that antitu-
mour effects of NSAIDs are medi-
ated mainly by inhibition of COX-2 
and subsequent reduction of pros-
taglandin synthesis (Wang and Du-
bois, 2010b).  
COX-2 is expressed in neurons 
of normal human brain tissue (Yaso-
jima et al., 1999; Joki et al., 2000). 
Overexpression of COX-2 has been 
reported in astrocytomas (Deininger 
et al., 1999; Joki et al., 2000; Shono 
et al., 2001) and in oligodendroglio-
mas (Castilla et al., 2003). Elevated 
COX-2 is correlated with high histo-
logical grade (Joki et al., 2000) and 
poor prognosis (Shono et al., 2001; 
Castilla et al., 2003) in gliomas. 
HuR 
Hu proteins are a family of four 
RNA-binding proteins that partici-
pate in post-transcriptional regula-
tion of RNA. HuB, HuC and HuD 
are primarily expressed in neurons 
and have important functions in 
neuronal development and memory 
(Hinman and Lou, 2008). HuR is 
ubiquitously expressed in human 
tissues and is predominantly present 
in the nucleus (Lopez de Silanes et 
al., 2005). HuR is able to shuttle be-
tween the nucleus and cytoplasm, 
which is considered a main mecha-
nism for its RNA-stabilising func-
tion (Doller et al., 2008). HuR 
overexpression can increase the half-
life of its target RNAs such as RNA 
of TNFα (Dean et al., 2001). HuR 
also binds to mRNA of VEGF and 
COX-2 and regulates their expres-
sion (Levy et al., 1998; Sengupta et 
al., 2003; Mrena et al., 2005; Young 
et al., 2009). Cytoplasmic expression 
of HuR is associated with high 
COX-2 expression in carcinomas of 
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the colon, ovary and stomach 
(Erkinheimo et al., 2003; Mrena et 
al., 2005; Denkert et al., 2006). 
Furthermore, cytoplasmic HuR ex-
pression is an independent prog-
nostic factor in cancers of the breast 
(Heinonen et al., 2005) and ovary 
(Denkert et al., 2004a). Expression 
of HuR has been found in brain 
tumours such as gliomas and 
medulloblastomas (Nabors et al., 
2001; Ido et al., 2008). 
Mechanisms of glioma invasion 
Gliomas have an inherent tendency 
to infiltrate the surrounding brain. 
This growth pattern usually prevents 
their complete neurosurgical resec-
tion. Infiltrative growth is histologi-
cally seen already in low-grade 
gliomas. Unlike in many organs, 
basal membrane does not inhibit 
tumour cell invasion in brain paren-
chyma. In brain, well-defined basal 
membrane is limited to subpial and 
perivascular locations. Mechanisms 
involved in glioma cell invasion to 
surrounding brain include detach-
ment of the cell from its original site, 
attachment to the extracellular ma-
trix (ECM) and proteolytic degrada-
tion of ECM (Nakada et al., 2007). 
These alterations facilitate the sub-
sequent cell migration by modifica-
tions of the actin cytoskeleton. 
Typical invasion routes of malig-
nant glioma cells are along white 
matter tracts and basal laminas of 
blood vessels (Furnari et al., 2007). 
Haematogenous spread and metasta-
sis of malignant gliomas is extremely 
rare. There is experimental evidence 
that glioma cell lack the ability to 
invade intact blood vessels (Bern-
stein and Woodard, 1995). However, 
the molecular basis of this feature of 
malignant gliomas is not known. 
Proteases including matrix metal-
loproteinases (MMP2, MMP9), 
urokinase type plasminogen activator 
(uPA) and cathepsin B are expressed 
in gliomas by grade dependent man-
ner and they have a potential role in 
glioma cell invasion (Rao, 2003). 
Tumour cell proliferation 
Mitotic activity 
Mitotic activity is one of the four 
major histopathological grading cri-
teria of gliomas, with the others be-
ing atypia, microvascular prolif-
eration and necrosis. The presence 
of mitotic activity separates grade 
III-IV tumours from grade II. In the 
current WHO classification, the 
numbers of mitotic figures for dif-
ferent grades are not defined. Occa-
sional mitoses in grade II gliomas are 
accepted (Louis et al., 2007). In the 
St. Anne/Mayo grading scheme for 
astrocytomas even single mitotic 
figure is a criterion for grade III. 
However, the clinical behaviour of 
astrocytomas with a solitary mitosis 
is more like that of grade II tumours 
supporting tolerance for occasional 
mitoses in clinical practice (Giannini 
et al., 1999).  
KI-67 / MIB-1 labelling index 
In clinical neuropathology glioma 
grading can be problematic due to 
small histological samples or the ab-
sence of mitotic figures in an other-
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wise anaplastic tumour. Immuno-
histochemical labelling of proliferat-
ing cells with monoclonal antibody 
MIB-1 has become an invaluable aid 
in glioma diagnostics. MIB-1 anti-
body recognizes a nuclear Ki-67 an-
tigen, which is expressed in the cell 
cycle except the resting phase G0 
(Cattoretti et al., 1992). 
The tumour proliferation index 
as measured by the fraction of MIB-
1-positive tumour cells correlates 
with histological grade and survival 
in astrocytomas (Sallinen et al., 1994; 
Wakimoto et al., 1996; Giannini et 
al., 1999). Prognostic significance of 
MIB-1 index has also been shown in 
oligodendrogliomas (Heegaard et al., 
1995; Kros et al., 1996; Dehghani et 
al., 1998). 
Apoptosis and apoptotic index 
Apoptosis or programmed cell death 
is a physiological characteristic of 
cells during embryogenesis and adult 
life enabling normal turnover of tis-
sues (Holcik et al., 2005). Apoptosis 
can be found in malignant tumours 
where it determines tumour net 
growth together with cell prolifera-
tion. Tumour cell apoptosis can be 
spontaneous or it can be induced by 
irradiation or chemotherapeutic 
agents (Kerr et al., 1994). Apoptotic 
cells can be quantified in tissue sec-
tions to calculate the apoptotic index 
of the tumour (Gavrieli et al., 1992). 
In gliomas, the apoptotic rate does 
not correlate with prognosis (Schif-
fer et al., 1995; Heesters et al., 1999). 
Angiogenesis and 
microvascular proliferation 
Angiogenesis in gliomas is a complex 
process involving tumour cells, en-
dothelial cells, growth factors and 
their receptors as well as extracellular 
matrix. Cerebral capillaries are 
formed by endothelial cells and their 
basal lamina, which are enveloped by 
pericytes and astrocytic foot proc-
esses (Ballabh et al., 2004). These 
cells form the blood-brain barrier, 
which inhibits the exchange of 
molecules between the bloodstream 
and brain. Tight junctions (zonula 
occludens) between endothelial cells 
are the main anatomical component 
of the blood-brain barrier. 
Angiogenesis plays an important 
role in glioma growth and progres-
sion. Neovascularisation in gliomas 
means an increase in vascular density 
and formation of abnormal vascular 
structures (Figure 4). Microvessel 
density correlates with tumour grade 
in astrocytomas (Leon et al., 1996). 
Vascular density is also an independ-
ent prognostic factor in adult astro-
cytomas (Leon et al., 1996; 
Abdulrauf et al., 1998; Birlik et al., 
2006). The blood-brain barrier of 
brain tumour vessels is defective 
because the endothelial cells lack 
tight junctions, and the vessels are 
enveloped by only a few pericytes or 
astrocytic foot processes. Conse-
quently, these defects lead to the 
accumulation of fluid and plasma 
proteins in the extracellular space 
and peritumoural vasogenic oedema 
(Furnari et al., 2007). The brain lacks 
lymphatic vessels through which the 
extravasated fluid is transported 
back into circulation in other organs. 
Thus, in the brain the extravasated 
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fluid must move within the narrow 
extracellular space, which further 
enhances the oedema. 
Microvascular proliferation is a 
hallmark of glioblastomas, but it can 
also be found in anaplastic oligoden-
drogliomas. Microvascular prolifera-
tion is not a categorical sign of 
malignancy, however. It may be pre-
sent in benign pilocytic astrocytomas 
without any prognostic significance. 
A dramatic shift in tumour angio-
genesis is seen in the transition from 
low-grade and anaplastic astrocy-
tomas to glioblastomas. The most 
common feature of microvascular 
proliferation is capillary tufts resem-
bling glomeruli in the kidney (Figure 
4). Previously, these glomeruloid 
vessel structures were called endo-
thelial cell proliferation. However, 
because they consist of both multi-
layered endothelial cells and peri-
cytes/smooth muscle cells 
(Wesseling et al., 1995), they were 
renamed microvascular proliferation. 
Molecular mechanisms of 
angiogenesis 
The molecular basis of glioma an-
giogenesis is complex and several 
mechanisms have been introduced. 
Angiogenesis in gliomas is driven by 
hypoxia and it is mediated by hy-
poxia inducible factor (HIF-1), 
which is a transcription factor se-
Figure  4  Vascular patterns of gliomas. A, dense network of capillaries in 
oligodendroglioma. B, highly vascular glioblastoma with plump, 
multilayered endothelial cells. C and D, microvascular prolifera-
tion of glioblastoma with glomeruloid structures. 
Review of the literature 
34 
creted by pseudopalisading tumour 
cells of glioblastoma (Fischer et al., 
2005). HIF-1 consists of two sub-
units HIF-1α and HIF-1β. HIF-1 
regulates the transcription of several 
genes that are involved in angio-
genesis, tumour cell growth and in-
vasion (Semenza, 2010). Vascular 
endothelial growth factor (VEGF) 
expression of tumour cells is acti-
vated by HIF-1 (Semenza, 2010). 
VEGF and platelet-derived 
growth factor (PDGF) are key an-
giogenic mediators in glioblastomas. 
VEGF (or VEGF-A) belongs to the 
growth factor family with four other 
members: placenta growth factor 
(PlGF), VEGF-B, VEGF-C and 
VEGF-D (Lohela et al., 2009). 
VEGF and PDGF are produced by 
perinecrotic tumour cells and induce 
angiogenesis (Hermanson et al., 
1992; Plate et al., 1992). VEGF in-
creases vascular permeability of both 
existing and newly formed vessels 
(Fischer et al., 2005). VEGF is 
highly expressed in malignant glio-
mas (Plate et al., 1992; Hatva et al., 
1995) and correlates with microves-
sel density of the tumours (Schmidt 
et al., 1999).  
VEGFR 1 and 2 are tyrosine 
kinase receptors of VEGF, which 
are expressed in endothelial cells of 
high-grade gliomas, but not in nor-
mal brain endothelium (Plate et al., 
1994). VEGF secreted by tumour 
cells binds to VEGFR2 on the endo-
thelial cells, resulting in the paracrine 
signalling loop that stimulates endo-
thelial cell growth and division 
(Norden et al., 2009). 
The PDGF signalling pathway is 
involved in tumourigenesis and in 
the progression of gliomas by pro-
moting cell proliferation and angio-
genesis. The PDGF family consists 
of four ligands PDGFA-D and their 
receptors PDGFRA and PDGFRB 
(Shih and Holland, 2006). PDGFB 
and its receptor PDGFRB, are ex-
pressed in hyperplastic endothelial 
cells in glioblastoma (Hermansson et 
al., 1988; Hermanson et al., 1992). 
The angiogenic effect of PDGFB is 
at least partly mediated by the 
upregulation of VEGF expression 
(Guo et al., 2003). 
Alternative mechanisms for vas-
cularisation have been found in a 
subset of glioblastomas. In the ex-
perimental glioma model, the tu-
mour may co-opt existing host 
vessels. The co-opted vasculature 
supports the tumour until the 
neoangiogenesis starts (Holash et al., 
1999). In vasculogenic mimicry, 
glioblastoma cells presenting stem 
cell properties may express endothe-
lium-associated genes and form 
blood vessels de novo (El Hallani et 
al., 2010). Recent studies have 
shown that endothelial cells of 
glioblastomas harbour the same ge-
netic alterations with tumour cells 
such as EGFR amplification (Ricci-
Vitiani et al., 2010; Wang et al., 
2010). These results suggest that a 
subpopulation of endothelial cells of 
glioblastoma originate from tumour 
stem-like cells. 
Diagnostics and 
treatment of gliomas 
Magnetic resonance imaging 
Magnetic resonance imaging is cur-
rently the method of choice in brain 
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tumour imaging. MRI is an invalu-
able tool in preoperative diagnostics 
and anatomical localization of glio-
mas as well as in the planning of the 
surgical treatment. Postoperatively 
MRI is utilized in planning radio-
therapy, assessing response to treat-
ment and tumour progression 
(Henson et al., 2005). 
MRI with contrast medium is the 
most sensitive non-invasive diagnos-
tic method in neuro-oncology (Jen-
kinson et al., 2007). Administration 
of intravenous paramagnetic gado-
linium-DTPA improves contrast in 
MR imaging and increases sensitivity 
in brain tumour diagnostics (Felix et 
al., 1985; Brant-Zawadzki et al., 
1986). Contrast-enhanced MRI is 
useful in differentiating tumours 
from other pathological processes of 
the CNS (Essig et al., 2006).  
The intact blood-brain-barrier is 
impermeable to water-soluble gado-
linium chelates, and it prevents the 
access of contrast medium into brain 
tissue (Neuwelt, 2004). Therefore, 
contrast enhancement in MRI is a 
sign of a disrupted blood-brain-
barrier reflecting the tumour-
induced abnormal neovascularisation 
(Essig et al., 2006). 
MRI characteristics correlate with 
the WHO grade of diffuse gliomas 
(Henson et al., 2005; Jenkinson et al., 
2007). In low-grade gliomas, MRI 
usually shows a mildly expansive 
lesion without contrast enhancement 
or substantial oedema. In anaplastic 
grade III tumours, there is character-
istically more oedema and expansion 
into the surrounding brain with 
patchy areas of gadolinium en-
hancement. The typical MRI appear-
ance of glioblastoma shows irregular 
or ring-like contrast enhancement 
with a central non-enhancing area 
corresponding to necrosis. Glioblas-
tomas produce a pronounced mass 
effect and vasogenic oedema as well. 
Although gadolinium enhancement 
is associated with anaplastic features 
in gliomas, up to one third of the 
non-enhancing gliomas are his-
tologically malignant (Barker et al., 
1997; Scott et al., 2002). Further-
more, benign pilocytic astrocytomas 
often show intense contrast en-
hancement reflecting the microvas-
cular proliferation that is an 
exceptional feature in a benign as-
trocytoma (Zimmerman and Bi-
laniuk, 2009). 
Functional MRI techniques can 
be utilised preoperatively to identify 
eloquent brain areas (Vlieger et al., 
2004). The functional information 
can be applied for planning neuro-
surgical operations in order to 
minimize damage to eloquent brain 
regions. 
The association between MRI 
characteristics and molecular profiles 
of gliomas have been reported re-
cently. Oligodendrogliomas that 
harbour the 1p/19q deletion are in-
frequently located in temporal lobes 
and show indistinct borders in MRI 
(Zlatescu et al., 2001; Megyesi et al., 
2004; Jenkinson et al., 2006; Kim et 
al., 2011). Secondly, fuzzy tumour 
borders in the MRI of glioblastomas 
may predict EGFR amplification at 
the molecular level (Aghi et al., 
2005). Furthermore, the volume ra-
tio of contrast enhancement and 
tumour necrosis in MRI correlates 
with EGFR overexpression in 
glioblastomas (Diehn et al., 2008). 
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Positron emission tomography 
Positron emission tomography 
(PET) is an imaging method that can 
be used to measure brain metabo-
lism. PET detects radionuclide-
labelled tracer molecules such as 
[18F]fluorodeoxyglucose (FDG) and 
[11C]methionine (MET), which re-
flect glucose and amino acid uptake 
of the brain tissue, respectively 
(Minn, 2005). The advantage of PET 
in tumour imaging is based on en-
hanced energy metabolism of cancer 
cells compared to normal tissue. 
However, the basal level of glucose 
metabolism in brain is high, resulting 
in a low signal-background ratio in 
FDG-PET. Generally, high-grade 
gliomas show increased glucose me-
tabolism in PET, while low-grade 
gliomas are hypometabolic (Di 
Chiro, 1987; Padma et al., 2003). 
Background uptake of amino 
acid tracers in normal brain tissue is 
low, which allows high contrast for 
tumour uptake (Jager et al., 2001). 
MET uptake in PET is associated 
with glioma grade and survival 
(Ogawa et al., 1993; Nuutinen et al., 
2000; De Witte et al., 2001). FDG 
and MET uptake in brain tumours is 
independent of blood-brain-barrier 
disruption, which is advantageous in 
tumour imaging (Minn, 2005). A 
recent study suggests that PET can 
be used to detect glioma cell inva-
sion into white matter tracts, which 
were visualised by diffusion tensor 
MRI (Stadlbauer et al., 2009). 
Currently, the main indications 
for PET in the imaging of gliomas 
are detecting tumour recurrence and 
guiding diagnostic biopsy site. PET 
using FDG or MET is more sensi-
tive than standard MRI to detect 
glioma recurrence (Minn, 2005). 
However, specificity of PET in dif-
ferentiating between radiation injury 
and true recurrence is 75% (Dher-
main et al., 2010). PET can be used 
to direct biopsy to hypermetabolic 
tumour tissue and avoid reactive 
changes on the tumour edge (Klas-
ner et al., 2010). 
Molecular diagnostics 
Genetic alterations are important 
steps in gliomagenesis as well as 
biomarkers in diagnostics. Tradition-
ally, genetics of gliomas have been 
studied by basic cytogenetic methods 
like G band karyotyping and fluores-
cence in situ hybridisation (FISH). 
Modern techniques for studying ge-
netic aberrations include whole ge-
nome karyotyping by comparative 
genomic hybridisation (CGH) and 
array-based CGH (aCGH) (Kalli-
oniemi et al., 1992; Pinkel et al., 
1998).  
Currently, testing of 1p/19q dele-
tions by either FISH or aCGH is 
recommended for oligodendroglial 
tumours to complement histopa-
thological diagnosis and to add 
prognostic information of the tu-
mour (Yip et al., 2008; Jansen et al., 
2010). The EGFR amplification as-
say is a useful diagnostic aid in small 
tumour biopsies with only few infil-
trating neoplastic cells, where histo-
pathological criteria alone do not 
allow diagnosis of malignant glioma. 
Identification of tumour cells with 
EGFR amplification by FISH (Mott 
et al., 2008) or by chromogenic in 
situ hybridisation (CISH) (Järvelä et 
al., 2006) can be used as a surrogate 
marker for high-grade astrocytoma.  
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The methylation status of the 
MGMT promoter provides prognos-
tic information of glioblastomas. 
However, the lack of standardised 
methods has inhibited the wide use 
of MGMT testing in clinical neuro-
pathology (von Deimling et al., 
2011). Furthermore, it is not yet 
known which CpG sites are relevant 
for silencing of MGMT transcription 
(Riemenschneider et al., 2010). 
An immunohistochemical assay 
of the p.R132H IDH1 mutation may 
be helpful in differential diagnostics 
of diffuse gliomas. Positive IDH1 
immunostaining can rule out pilo-
cytic astrocytomas and ependymo-
mas, which lack IDH1 mutations 
(Capper et al., 2010). Moreover, 
IDH1 immunohistochemistry helps 
in the discrimination of oligoden-
drogliomas from tumours with simi-
lar morphology, such as central 
neurocytomas and dysembryoplastic 
neuroepithelial tumours (Capper et 
al., 2011). Assessment of IDH1 and 
p53 immunohistochemistry is useful 
in differentiating reactive gliosis 
from astrocytoma, which is a com-
mon diagnostic problem in surgical 
pathology (Camelo-Piragua et al., 
2011). However, negative staining 
with IDH1 antibody to mutant 
p.R132H does not rule out other 
IDH1 mutations that are present in 
less than 10% of mutated cases or 
rare IDH2 mutation. 
Treatment of gliomas 
Surgery 
The current treatment options for 
diffuse gliomas include surgical re-
section, radiotherapy and chemo-
therapy (Tabatabai et al., 2010). The 
goals for surgical resection are de-
creasing the tumour mass, lowering 
intracranial pressure and confirming 
the diagnosis. Surgical treatment is 
not curative because of the infiltra-
tive nature of diffuse gliomas. The 
impact of the extent of surgical re-
section on patient survival has been 
controversial (Sanai and Berger, 
2008). A recent meta-analysis indi-
cates that cytoreductive resection of 
malignat glioma is associated with 
better survival as compared to bi-
opsy (Tsitlakidis et al., 2010). How-
ever, in elderly patients the benefit 
from open surgery seems to be lim-
ited (Vuorinen et al., 2003). If surgi-
cal resection is not feasible because 
of tumour location, a stereotactic 
biopsy should be performed to ob-
tain tissue for histopathological di-
agnostics and molecular studies 
(Wen and Kesari, 2008; Soffietti et 
al., 2010). 
Radiotherapy 
Radiotherapy is an effective treat-
ment of malignant gliomas and pro-
longs the survival of the patients 
(Walker et al., 1978). The standard 
therapy for anaplastic gliomas 
(WHO grade III) consists of adju-
vant radiotherapy after surgery 
(Stupp et al., 2010). The total dose of 
focal radiotherapy for malignant 
gliomas is 50-60 Gy (Laperriere et 
al., 2002; Wen and Kesari, 2008). In 
low-grade gliomas, radiotherapy ex-
tends the patients’ progression-free 
period, but does not affect their 
overall survival (van den Bent et al., 
2005). Adjuvant radiotherapy is indi-
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cated for low-grade glioma patients 
with unfavourable prognostic factors 
such as incomplete surgical resection 
or advanced age (Soffietti et al., 
2010). Radiotherapy may induce 
long-term adverse reactions includ-
ing cognitive impairment and leu-
koencephalopathy (Surma-aho et al., 
2001). 
Chemotherapy 
The blood-brain barrier restricts the 
entry of many chemotherapeutic 
agents into the CNS. In high-grade 
gliomas, the blood-brain-barrier is 
often partially disrupted due to 
neoangiogenesis of the tumour, 
which may facilitate drug delivery to 
the tumour (Muldoon et al., 2007). 
The main chemotherapeutic 
agents currently used in treatment of 
gliomas are alkylating drugs such as 
temozolomide, lomustine (CCNU 1-
(2-Chloroethyl)-3-Cyclohexyl-1-
Nitrosourea) and procarbazine, 
which are able to cross the blood-
brain-barrier (Rao and Buckner, 
2004). Combined treatment with 
procarbazine, CCNU and vincristine 
(PCV chemotherapy) is particularly 
effective in anaplastic oligodendro-
gliomas with 1p/19q deletion 
(Cairncross et al., 1998). 
In low-grade gliomas, chemo-
therapy is mainly used for tumour 
recurrences after surgical resection 
and radiotherapy (Soffietti et al., 
2010). Adjuvant PCV chemotherapy 
does not prolong survival of patients 
with anaplastic oligodendroglial tu-
mour compared to radiotherapy 
alone (Cairncross et al., 2006; van 
den Bent et al., 2006). Concomitant 
chemotherapy and radiation (chemo-
radiotherapy) are currently the 
treatments of choice for glioblas-
toma. Patients who receive concomi-
tant temozolomide and radiotherapy 
have significantly longer survival 
compared to patients with radiother-
apy alone (median survival 14.6 vs. 
12.1 months) (Stupp et al., 2009). 
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AIMS OF THE STUDY 
The purpose of this thesis was to study molecular alterations involved in glioma 
progression. Therefore, we collected a retrospective series of gliomas from pa-
tients who had been operated on for glioma and one or more recurrences. 
 
Specifically, we studied: 
 
1. the correlation of tumour contrast enhancement in MRI with mi-
crovessel density and cell proliferation in gliomas (study I) 
 
2. the genetic alterations and proteins related to recurrence and pro-
gression of gliomas (studies II-IV) 
 
3. the molecular changes in the longitudinal course of individual glio-
mas (studies II-IV) 
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MATERIALS AND METHODS 
Tissue samples 
This retrospective study included 
diffuse gliomas diagnosed at the De-
partment of Pathology, University of 
Helsinki and HUSLAB, Helsinki, 
Finland between 1979 and 2000. All 
patients were operated on at the De-
partment of Neurosurgery, Helsinki 
University Central Hospital, Hel-
sinki, Finland. Formalin-fixed and 
paraffin-embedded tumour samples 
were retrieved from the archive, and 
the histopathological diagnoses were 
reviewed by the author and experi-
enced neuropathologist (A.P.). All 
tumours were diagnosed according 
to the latest WHO classification at 
the time of the study (Kleihues et al., 
1993; Kleihues and Cavenee, 2000; 
Louis et al., 2007). 
Primary supratentorial astrocy-
tomas, oligodendrogliomas and oli-
goastrocytomas, grade II-IV, from 
62 patients were included in study I. 
Studies II and IV included 229 pri-
mary and recurrent astrocytomas, 
oligodendrogliomas and oligoastro-
cytomas, grade II-IV, from 113 pa-
tients. Study III included primary 
and recurrent astrocytomas, oli-
godendrogliomas and oligoastrocy-
tomas, grade II-IV, from 87 patients. 
Magnetic resonance 
imaging (study I) 
Magnetic resonance imaging of the 
62 patients in study I was performed 
preoperatively using a Magnetom 42 
SP 1.0 Tesla imager (Siemens, Erlan-
gen, Germany). Sagittal T1-weighted 
localizing images, unenhanced T1-, 
T2- and proton-weighted spin echo 
images were obtained. The contrast 
agent gadopentetate dimeglumine 
(Magnevist, Schering AG, Berlin, 
Germany) was injected intravenously 
0.1 mmol/kg, and axial T1-weighted 
spin echo images were repeated after 
5-10 minutes. Contrast enhancement 
was studied in T1-weighted post-
contrast images by two radiologists. 
Any detectable contrast enhance-
ment of the tumour was considered 
positive. 
Immunohistochemistry 
Tissue microarray (TMA) blocks 
were prepared for studies II-IV with 
a manual tissue array instrument 
(Beecher Instruments, Sun Prairie, 
WI, USA). A representative area of 
the tumour was selected in H&E-
stained sections, and 1-3 tissue cyl-
inders with a 0.6 mm diameter were 
obtained from each tumour. Four-
micrometer sections (5 μm in study 
III) were cut from TMA blocks and 
conventional paraffin blocks for 
immunohistochemistry. 
The antibodies used in immuno-
histochemical studies are summa-
rized in Table 2. In study I, capillary 
endothelium was highlighted by 
polyclonal antibody against factor 
VIII-related antigen (FVIII, Dako, 
Glostrup, Denmark, dilution 
1:2000). The slides were pretreated 
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Table  2 Antibodies used in immunohistochemical studies. 
Antibody Clonality Host Dilution Pretreatment Study
Factor VIII Polyclonal Rabbit 1:2000 Pepsin I
MIB-1 (Ki-67 ) Monoclonal Mouse 1:50 Heating I
Ezrin Monoclonal Mouse 1:2000 Heating II
KIT (CD117) Polyclonal Rabbit 1:300 Heating III
VEGFR2 (Flk-1) Polyclonal Rabbit n.a. Heating III
EGFR Monoclonal Mouse 1:150 Heating III
p53 Monoclonal Mouse 1:500 Heating III
Nestin Monoclonal Mouse 1:500 Heating III
Prominin 1 (CD133) Monoclonal Mouse 1:10 Heating III
COX-2 Monoclonal Mouse 1:100 Heating IV
HuR Monoclonal Mouse 1:20000 Heating IV  
 
 
with pepsin and the primary anti-
body was detected using the Vec-
tastain Elite ABC Kit (Vector 
Laboratories, Burlingame, CA). Tu-
mour cell proliferation was detected 
by monoclonal antibody MIB-1/Ki-
67 (Immunotech S.A., Marseille, 
France, dilution 1:50). Antigen re-
trieval was performed in a micro-
wave oven (15 min. in 10mM citrate 
buffer). A histostain-SP kit (Zymed 
Laboratories Inc., San Francisco, 
CA) was used to visualize the pri-
mary antibody. 
In study II, monoclonal antibody 
against human ezrin was used (clone 
3C12, dilution 1:2000) (Böhling et 
al., 1996). The monoclonal antibody, 
raised against the carboxyterminal 
part of ezrin (amino acids 362 to 
585), detects a single 80 kDa band 
compatible with ezrin in im-
munoblotting. Antigen retrieval was 
performed in a microwave oven (10 
min. in 10mM citrate buffer). The 
slides were stained using a LabVision 
Autostainer automatic immunostain-
ing device and UltraVision detection 
kit (Lab Vision Inc., Fremont, CA).  
In study III, the following anti-
bodies were used: polyclonal 
KIT/CD117 antibody (A 4502, 
Dako, Glostrup, Denmark, dilution 
1:300), monoclonal EGFR antibody 
(NCL-EGFR, Novocastra Laborato-
ries Ltd., Newcastle, United King-
dom, dilution 1:150), monoclonal 
p53 antibody (NCL-p53-D07, No-
vocastra Laboratories Ltd., Newcas-
tle, United Kingdom, dilution 1:500) 
and polyclonal VEGFR2 antibody 
(Flk-1/ VEGFR2 Ab-1, NeoMark-
ers, LabVision Corp., Fremont, CA). 
Antigen retrieval for KIT staining 
was performed in a microwave oven 
(7 min and 3 × 5 min in Tris-EDTA 
buffer, pH 9.0). Autoclave heating 
was used as pretreatment for EGFR 
and p53 antibodies (120ºC, 2 min in 
1× Reveal buffer; Biocare Medical, 
Walnut Creek, CA) and for 
VEGFR2 (120ºC, 2 min in a10 mM 
citrate buffer, pH 6.0). The binding 
of KIT antibody was detected with a 
Dako EnVision detection kit (Per-
oxidase/DAB, rabbit/mouse, Dako). 
The EGFR, p53 and VEGFR2 anti-
bodies were visualized with Powervi-
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sion+ Poly-HRP detection kit 
(DPVB+110DAB, ImmunoVision 
Technologies Co., Daly City, CA). 
In study IV, monoclonal antibod-
ies against COX-2 (dilution 1:100) 
and HuR (dilution 1:20000, clone 
19F12) were used. For antigen re-
trieval, the sections were pretreated 
in for 20 min at 85°C in Tris-HCl 
buffer (pH 8.5). Immunostainings 
were performed with a Lab Vision 
Autostainer 480 and Dako REAL 
EnVision detection kit. All tissue 
sections were counterstained with 
hematoxylin. 
Scoring of 
immunohistochemical 
stainings 
In study I, microvessel density was 
measured from the most vascular-
ised area of the tumour. The number 
of FVIII positive vessels was 
counted from three microscopic 
fields (1.3 mm2 each). The average of 
three counts was considered as the 
vascular density of the tumour. In 
cases of the multiluminal hyperplas-
tic vessel, each lumen was consid-
ered as one capillary. The cell 
proliferation rate was measured from 
the most proliferative area of the 
tumour. The cell proliferation index 
was defined as a percentage of MIB-
1-positive tumour cells. At least 500 
tumour cells were analysed in each 
tumour. 
In study II, two observers (the 
author and O.C.) evaluated ezrin 
expression independently. Immu-
nostaining was graded from 0 to 3 
using these ranges: 0%, 1-30%, 31-
70% and >70% positive tumour 
cells respectively. Grading of the two 
observers was averaged. 
In study III, the KIT, EGFR, 
p53, VEGFR2, nestin and prominin-
1 immunostainings were graded 
semiquantitatively as either negative 
(-), faintly positive (+), moderately 
positive (++) or strongly positive 
(+++). 
In study IV, granular cytoplasmic 
staining with COX-2 antibody was 
considered positive and scored as 
low (0-20% of tumour cells) or high 
(>20% of tumour cells). HuR stain-
ing was scored as negative (only nu-
clear staining in tumour cells) or 
positive (cytoplasmic staining in tu-
mour cells). 
Immunoblotting (study II) 
Ezrin expression was confirmed by 
an immunoblotting assay of eight 
gliomas. Fresh tumour samples were 
snap frozen and stored in liquid ni-
trogen. Tumour samples were ho-
mogenized in RIPA buffer and 
protein concentration was measured. 
Equal amounts of protein (30 µg) 
were separated with SDS-PAGE 
electrophoresis in 10% polyacryla-
mide gel and blotted on nitrocellu-
lose sheet. The filter was blocked by 
incubating overnight in non-fat milk 
protein and incubated with mono-
clonal ezrin antibody (clone 3C12, 
dilution 1:1000) for 1 h. Anti-actin 
antibody was used to control the 
loaded protein in the gel. The pri-
mary antibody was detected using an 
ECL kit (Amersham Pharmacia Bio-
tech, Buckinghamshire, England). 
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Chromogenic in situ 
hybridisation and 
fluorescence in situ 
hybridisation (study III) 
In study III, bacterial artificial chro-
mosome (BAC) probes were used to 
study gene copy numbers of KIT 
(clone RP11-586A2), PDGFRA 
(RP11-231C18), VEGFR2 (RP11-
662M13) and EGFR (RP11-815K24) 
(Invitrogen Ltd, Paisley, UK). The 
BAC DNA was isolated and labelled 
with a DIG-Nick translation mix 
(Roche, Mannheim, Germany). Pre-
treatment for in situ hybridisation 
was performed in a microwave oven 
(92ºC, 10 min in 0.1 M Tris-HCl 
buffer, pH 7.0) and by enzymatic 
digestion (Digest-All 3 solution, 
Zymed, Inc., South San Francisco, 
CA). The probes were applied onto 
the slides, sections were denatured 
and hybridisation was done over-
night at 37ºC. The probes were de-
tected with mouse anti-digoxigenin 
antibody (dilution 1:300; Roche Bio-
chemicals, Mannheim, Germany) 
and a Powervision+ kit (ImmunoVi-
sion Technologies). The tissue sec-
tions were counterstained with 
hematoxylin. 
Chromogenic in situ hybridisa-
tion showed weak or absent KIT, 
PDGFRA or VEGFR2 signals in 13 
tumours. Therefore, fluorescence in 
situ hybridisation was performed to 
study gene copy numbers in those 
tumours. The BAC DNA probes 
described earlier were labelled with a 
DIG-Nick and BIOTIN-Nick trans-
lation mix (Roche, Mannheim, Ger-
many). Centromeric probes for 
chromosomes 4 and 7 (CEP 4 and 
CEP 7, Vysis Inc., Downers Drive, 
IL) were used as controls. After hy-
bridisation, the probes were detected 
immunochemically with avidin-
fluorescein isothiocyanate and anti-
digoxigenin rhodamine. Slides were 
counterstained with DAPI in anti-
fade solution and viewed under a 
fluorescence microscope. 
Gene amplification was defined 
as 6 or more hybridisation signals 
per nucleus. Tumours with 3-5 sig-
nals were considered aneuploid. 
Screening of p53 gene 
mutations (study III) 
Polymerase chain reaction (PCR), 
denaturing high-performance liquid 
chromatography (DHPLC) and 
DNA-sequencing methods were 
used for studying p53 mutations. 
These methods are described in de-
tail in the original publication. 
Statistical analysis 
Associations between categorical 
variables were studied using the χ2 
test and Fischer’s exact test. Differ-
ences of non-normally distributed 
variables between two or more 
groups were compared with the non-
parametric Mann-Whitney U test 
and Kruskall-Wallis test. Paired ob-
servations of primary and recurrent 
gliomas were studied using the Wil-
coxon signed rank test. Level of in-
terobserver agreement was assessed 
by kappa statistics. The relationship 
between continuous variables was 
studied using simple linear regres-
sion and Spearman rank correlation. 
Survival analysis was performed us-
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ing the Kaplan-Meier method and 
survival curves were compared using 
the log-rank test. Multivariate sur-
vival analysis was performed using 
Cox proportional hazards model. 
The statistical significance level was 
set at 5%. Statistical analysis was 
performed using Statview (SAS In-
stitute Inc., San Francisco, CA) and 
SPSS (SPSS Inc., Chicago, IL) statis-
tical software. 
Approvals 
This study was approved by the 
Ethical Committee of the Hospital 
District of Helsinki and Uusimaa 
and the National Supervisory Au-
thority for Welfare and Health.
 
 45 
RESULTS AND DISCUSSION 
MRI enhancement and 
histological features of 
gliomas (study I) 
We studied the correlation between 
MRI contrast enhancement and his-
tological characteristics of 62 diffuse 
gliomas (Table 3). Contrast en-
hancement in MRI was present in 45 
of 62 (73%) gliomas. Enhancement 
was seen in 23 of 38 (61%) low-
grade gliomas, in 11 of 13 (85%) 
anaplastic gliomas and in all 11 
glioblastomas. Contrast enhance-
ment in MRI was significantly asso-
ciated with higher tumour grade in 
the whole tumour group (p=0.005) 
and in the astrocytoma subgroup 
(n=51, p=0.006), but not in the oli-
godendroglial tumours. 
Grading of astrocytomas by MRI 
characteristics has been previously 
studied by Asari et al. (Asari et al., 
1994). They developed MRI scoring 
that was based on nine criteria: 1) 
tumour heterogeneity, 2) cyst forma-
tion or necrosis, 3) haemorrhage, 4) 
tumour crossing the midline, 5) oe-
dema and/or mass effect, 6) defini-
tion of border, 7) flow void, 8) 
degree of contrast enhancement and 
9) heterogeneity of contrast en-
hancement. Using this MRI scoring 
they could differentiate low-grade 
and high-grade astrocytomas. Degree 
and heterogeneity of contrast en-
hancement were related to histologi-
cal grade by multiple regression 
analysis (Asari et al., 1994). The MRI 
scoring developed by Asari et al. was 
later used in non-invasive grading of 
gliomas in two other studies (Rie-
Table  3 Tumour histology, WHO grade and contrast enhance-
ment of 62 gliomas (study I). 
Tumour histology and grade N Yes No
Astrocytoma
Grade II 31 19 12
Grade III 9 8 1
Grade IV 11 11 0
Oligodendroglioma
Grade II 4 3 1
Grade III 3 2 1
Oligoastrocytoma
Grade II 3 1 2
Grade III 1 1 0
Total 62 45 17
Contrast enhancement
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mann et al., 2002; Kumar et al., 
2006). In these studies, there was a 
significant difference in MRI score 
between low-grade and high-grade 
gliomas. Furthermore, the degree of 
contrast enhancement was one of 
the criteria that were significantly 
associated with tumour grade (Rie-
mann et al., 2002; Kumar et al., 
2006). Our results are in congruence 
with an earlier study by Aronen et 
al., where contrast enhancement in 
MRI imaging was associated with 
histological grade of diffuse gliomas 
(Aronen et al., 1994). One must keep 
in mind, though, that even benign 
pilocytic astrocytomas commonly 
show contrast enhancement in MRI 
(Zimmerman and Bilaniuk, 2009). 
However, pilocytic astrocytomas are 
usually sharply demarcated, whereas 
diffuse gliomas are ill-defined in 
MRI.  
Nonenhancing tumours should not 
be considered as low-grade merely 
based on their enhancement pattern. 
In our series, 2 of 17 (12%) nonen-
hancing gliomas were malignant (i.e. 
grade III-IV). In other studies, 9-
40% of nonenhancing tumours were 
histologically malignant (Barker et 
al., 1997; Ginsberg et al., 1998; Scott 
et al., 2002). 
Next, we studied the correlation 
of MRI contrast enhancement with 
endothelial proliferation, which is a 
hallmark of glioblastomas and char-
acteristic of anaplastic oligodendro-
gliomas as well. Tumour endothelial 
proliferation was significantly associ-
ated with contrast enhancement in 
MRI (p=0.003). All tumours (n=16) 
with endothelial proliferation in his-
tological sections showed contrast 
enhancement. This finding has been 
confirmed by Reiche et al., who 
studied oligodendrogliomas and 
found a significant association be-
tween contrast enhancement and 
tumour grade as well as endothelial 
proliferation (Reiche et al., 2002). 
Endothelial proliferation is not a sine 
qua non of contrast enhancement, 
however. We detected contrast en-
hancement in 63% of gliomas that 
did not have endothelial prolifera-
tion in histology. 
Correlation of MRI 
enhancement, tumour cell 
proliferation, vascular 
density and tumour grade 
(study I) 
In the present study, the mean vas-
cular density (i.e. the number of cap-
illaries per 1.3 mm2 microscopic 
field) was 53.2 in grade II, 98.9 in 
grade III and 149.8 in grade IV 
gliomas (p=0.001). The correlation 
between vascular density and tumour 
grade was found also in the sub-
group (n=45) that showed contrast 
enhancement in MRI (p=0.0017). 
Angiogenesis is necessary for tu-
mour growth. Without the forma-
tion of new vessels and 
establishment of perfusion, a tumour 
could not exceed a diameter of 2-3 
mm (Folkman, 1971). Intra-tumoural 
microvessel density is a reliable 
method for measuring angiogenic 
activity of solid tumours (Hasan et 
al., 2002). Immunohistochemically 
determined microvessel density is an 
independent prognostic factor in 
breast cancer (Weidner et al., 1992) 
and in several other epithelial can-
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cers as reviewed by Hasan and co-
workers (Hasan et al., 2002). 
Our results are in line with previ-
ous studies that found an association 
between microvessel density and 
tumour grade in astrocytomas (Leon 
et al., 1996; Wesseling et al., 1998). 
This association has been confirmed 
in later studies as well (Korkolopou-
lou et al., 2002; Quon et al., 2010). 
Furthermore, microvessel density is 
an independent prognostic factor in 
astrocytomas (Leon et al., 1996; Ab-
dulrauf et al., 1998; Birlik et al., 
2006). 
In our study, the immunohisto-
chemically assessed microvessel den-
sity was significantly higher in the 
tumours that showed MRI contrast 
enhancement compared to tumours 
with no enhancement (mean 47.9 vs. 
92.0, p=0.01). This finding most 
likely reflects a defective blood-
brain-barrier in newly formed blood 
vessels. Contrast enhancement in 
MRI is caused by the accumulation 
of intravenously administered gado-
linium-containing contrast material 
in the interstitial space (Jayaraman 
and Boxerman, 2009). In a normal 
brain, the blood-brain-barrier of the 
capillaries prevents the entrance of 
water-soluble contrast material in the 
interstitium. The current understand-
ing is that contrast enhancement in 
MRI is due to defective capillaries 
rather than the active destruction of 
the blood-brain-barrier of the exist-
ing vessels (Jayaraman and Boxer-
man, 2009). Neoangiogenesis of 
gliomas causes the formation of cap-
illaries that have fenestrated blood-
brain-barrier, which subsequently 
leads to the interstitial accumulation 
of contrast material in MRI. 
In our study, there was a signifi-
cant difference in the immunohisto-
chemically measured cell 
proliferation index between the 
nonenhancing and enhancing glio-
mas (mean 2.0% vs. 8.1%, p<0.001). 
Association between tumour en-
hancement and proliferation index 
may simply reflect that both vari-
ables are associated with the histo-
logical grade of the tumour. 
However, this result suggests that 
preoperative conventional MRI pro-
vides information on proliferation 
activity of the tumour. The fact that 
MRI contrast enhancement may be 
used as a non-invasive predictor of 
cell proliferation is clinically interest-
ing, because the immunohistochemi-
cally measured Ki-67 index is a 
widely used ancillary diagnostic 
method in approximating the clinical 
behaviour of gliomas. Previously, 
Aronen and co-workers have studied 
proliferative activity and MRI en-
hancement in diffuse gliomas. They 
found that mitotic activity of gliomas 
was associated with contrast en-
hancement in MRI (Aronen et al., 
1994). 
In their recent review Alexiou et 
al. have evaluated non-invasive 
methods for assessment of glioma 
proliferation (Alexiou et al., 2010). 
The imaging modalities that have 
been used for studying glioma pro-
liferation in vivo include MRI, PET 
and single-photon emission com-
puted tomography (SPECT). Alex-
iou et al. conclude that proton 
magnetic resonance spectroscopy 
(MRS), which provides information 
on the metabolic status of tumour 
tissue, is a promising tool for the 
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non-invasive assessment of glioma 
proliferation. 
In the present study, vascular 
density correlated positively with 
tumour cell proliferation of gliomas 
(r=0.51, p<0.0001). This association 
is not surprising because the cell 
proliferation index, as measured by 
Ki-67 (MIB-1) immunohistochemis-
try, correlates positively with glioma 
grade (Montine et al., 1994; Sallinen 
et al., 1994; Giannini et al., 1999; 
Sallinen et al., 2000). It has been 
suggested that the Ki-67 index could 
be included in the grading criteria of 
gliomas in the future (Kros, 2011). 
Functional MRI techniques can 
be used to characterise brain tu-
mours more accurately than conven-
tional contrast-enhanced MRI. 
Cerebral blood volume (CBV) can 
be measured in vivo by functional 
MRI techniques (Belliveau et al., 
1991). CBV studied by MR imaging 
can provide information on angio-
genesis and proliferation of gliomas 
as well. In high-grade gliomas CBV 
is significantly elevated compared to 
low-grade gliomas (Maia et al., 2005). 
Furthermore, CBV correlates with 
tumour vascularity and mitotic activ-
ity of gliomas (Aronen et al., 1994) 
as well as with metabolic activity and 
angiogenesis of gliomas (Aronen et 
al., 2000). Callot et al. found an asso-
ciation between CBV and endothe-
lial hyperplasia in low-grade gliomas 
(Callot et al., 2007). 
Ezrin is expressed in 
astrocytomas and oligo-
dendrogliomas (study II) 
We studied ezrin expression by im-
munohistochemistry in 229 primary 
and recurrent gliomas of 113 pa-
tients. Characteristics of the studied 
tumours are presented in Table 4. 
Ezrin expression was observed in 
both astrocytic and oligodendroglial 
tumours by immunohistochemistry 
and immunoblotting. The mean ez-
rin immunoreactivity score was 2.5 
in astrocytomas, 2.2 in oligoastrocy-
tomas and 2.1 in oligodendrogliomas 
(p=0.006). Oligodendrogliomas 
showed moderate staining in tumour 
cells and more intensive reactivity in 
astrocytic cells within the tumour. 
Ezrin immunoreactivity was associ-
ated with WHO grade in astrocy-
tomas (mean 2.4 in grade II vs. 2.4 
in grade III vs. 2.6 in grade IV, 
p=0.04) but not in oligodendroglio-
mas or oligoastrocytomas. In pair-
wise comparison, ezrin expression 
was significantly higher in glioblas-
tomas than in grade II astrocytomas 
(p=0.04, Mann-Whiney test with 
Bonferroni correction). Differences 
between grade II vs. III and grade 
III vs. IV were not significant. 
Ezrin expression was further 
confirmed by immunoblotting of 
frozen tumour samples in a subset of 
8 gliomas (2 astrocytomas, 2 
glioblastomas and 4 oligodendro-
gliomas). Immunoblotting for ezrin 
was positive in 3 oligodendrogliomas 
and in 1 glioblastoma. One low-
grade astrocytoma and one anaplas-
tic oligodendroglioma with negative 
immunoblotting were weakly posi-
tive for ezrin by immunohistochem-
istry. The other two tumours with 
negative immunoblotting were 
anaplastic astrocytoma and glioblas-
toma. These tumours showed mod-
erate or high positivity by 
immunohistochemistry. Negative 
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immunoblotting result may be due 
to tissue sampling, i.e. intratumoural 
heterogeneity and/or focal necrosis. 
Our results are in line with Gei-
ger et al., who found a positive cor-
relation between ezrin expression 
and WHO grade in 74 diffuse astro-
cytomas grade II-IV (Geiger et al., 
2000). However, 27 oligodendro-
gliomas were almost completely 
negative in ezrin immunohistochem-
istry in the series by Geiger et al. 
They found only a few positive as-
trocytic cells in the ezrin staining of 
oligodendrogliomas. The difference 
in the staining pattern in oligoden-
droglial tumours between the studies 
may be due to different antigen re-
trieval methods. We used heat-
induced antigen retrieval, which im-
proves the reactivity of the 3C12 
antibody in paraffin sections. Our 
results suggest that ezrin is linked to 
the malignant progression of astro-
cytomas. However, ezrin immuno-
histochemistry may not be directly 
applicable to the grading of gliomas 
because of considerable overlapping 
in ezrin scores between low-grade 
and high-grade gliomas. 
In a recent proteome-wide profil-
ing of low-grade oligoastrocytomas, 
ezrin was one of the proteins differ-
entially expressed in tumours with 
intact vs. deleted chromosome arms 
1p and 19q (Grzendowski et al., 
2010). Grzendowski et al. found that 
ezrin expression was significantly 
higher in tumours with intact chro-
mosomes 1p and 19q. Furthermore, 
they studied the hypermethylation of 
CpG islands of the ezrin gene and 
found that hypermethylation was 
associated with 1p/19q deletion. 
Table  4  Tumour histology, WHO grade and ezrin immunoreactivity  
(study II). 
Ezrin score Ezrin score
Tumour histology and grade N mean (SD) N mean (SD)
Astrocytoma
Grade II 42 2.4 (0.5) 16 2.5 (0.6)
Grade III 20 2.2 (0.7) 22 2.6 (0.5)
Glioblastoma, primary 14 2.6 (0.5) 13 2.8 (0.4)
Glioblastoma, secondary n.a. n.a. 24 2.6 (0.5)
Oligodendroglioma
Grade II 16 2.2 (0.6) 5 2.0 (0.4)
Grade III 8 2.1 (0.8) 15 2.0 (0.7)
Oligoastrocytoma
Grade II 6 2.0 (0.5) 6 2.3 (0.4)
Grade III 4 2.0 (0.8) 18 2.4 (0.6)
Total 110 119
SD standard deviation, n.a. not applicable
First diagnosis Recurrence
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However, hypermethylation of CpG 
islands did not decrease ezrin ex-
pression at the mRNA level to a sta-
tistically significant degree 
(Grzendowski et al., 2010). Grzen-
dowski et al. did not include survival 
analysis in their study of oligoastro-
cytomas. Nevertheless, it is interest-
ing that epigenetic silencing by 
hypermethylation of the ezrin gene is 
associated with 1p/19q deletion, 
which is a marker of favourable 
prognosis in oligodendroglial tu-
mours (Grzendowski et al., 2010). 
Ezrin and patient 
outcome in gliomas 
(study II) 
In the present study, ezrin expres-
sion was significantly higher in tu-
mour recurrences (mean ezrin score 
2.5 vs. 2.3, p=0.02), suggesting that 
ezrin is involved in the progression 
of gliomas. High ezrin expression of 
primary tumours was associated with 
shorter recurrence-free time (median 
3.6 vs. 4.1 vs. 2.5 in low, intermedi-
ate and high ezrin score respectively, 
p<0.05) and poor overall survival 
(median 9.2 vs. 7.7. vs. 4.5 years, 
p<0.05) in the whole tumour mate-
rial. The non-linear relationship be-
tween ezrin score and recurrence-
free time may be partly explained by 
the small number of cases in the low 
ezrin group (n=9). High ezrin ex-
pression was also a negative prog-
nostic factor for overall survival in 
the astrocytoma subgroup (p=0.03) 
but not in oligodendroglial tumours. 
However, in multivariate analysis, 
only WHO grade, histological tu-
mour type and patient age were in-
dependent prognostic factors. Ezrin 
expression was not independently 
associated with patient prognosis 
probably due to its correlation with 
tumour grade. 
Invasion and migration in brain 
tissue are characteristic of glioma 
cells. Destruction of brain structures 
and deterioration of neurological 
function due to infiltration of glioma 
cells are eventually fatal to the pa-
tient. Tumour cells of diffuse glio-
mas typically accumulate in subpial 
areas and perineuronally, and the 
cells preferentially invade along 
white matter tracts (secondary struc-
tures of Scherer). There is experi-
mental evidence that ezrin is linked 
to glioma cell migration in the brain. 
Wick and co-workers transfected 
mutant ezrin plasmids into four 
glioma cell lines that originally ex-
pressed wild-type ezrin (Wick et al., 
2001). Expression of mutant ezrin 
acted in a dominant negative manner 
in malignant glioma cells and inhib-
ited their migration in vitro. Fur-
thermore, when human glioma cells 
expressing a dominant-negative ezrin 
were xenografted in mouse brain 
they produced smaller tumours with 
longer survival time than controls 
(Wick et al., 2001). Similar results of 
the role of ezrin in tumour cell mo-
tility and invasion have been re-
ported in medulloblastoma cells 
(Osawa et al., 2009). 
EGFR amplification in 
gliomas (study III) 
In the present study, the EGFR am-
plification rate in secondary glioblas-
tomas was 14% in the 14 
 51 
informative cases (Table 5). Our 
results are well in line with Järvelä 
and co-workers, who studied EGFR 
amplification in 338 grade II-IV as-
trocytomas by CISH (Järvelä et al., 
2006). In their material, EGFR am-
plification was present in 16% of 
secondary glioblastomas.  
EGFR amplification is a genetic 
hallmark of primary glioblastomas. 
In a previous study, we found 
EGFR amplification in half of pri-
mary glioblastomas (Joensuu et al., 
2005). In a population-based study, 
the EGFR amplification frequency 
of glioblastomas was a little lower 
(36%) and secondary glioblastomas 
carried EGFR amplification in less 
than 10% of tumours (Ohgaki et al., 
2004).  
In the present study, the fre-
quency of EGFR amplification in 
anaplastic astrocytomas was 12% in 
primary tumours and 6% in recur-
rent tumours. We also detected 
EGFR amplification in two recur-
rent low-grade astrocytomas that did 
not show amplification at first diag-
nosis (Figure 5, cases 33 and 70). 
However, these two astrocytomas 
did not progress at histological level; 
both primary and recurrent tumours 
were WHO grade II. Järvelä et al. 
found EGFR amplification in 4% of 
grade II and in 21% of grade III as-
trocytomas (Järvelä et al., 2006). 
In our series, we found EGFR 
amplification in one (n=4) primary 
anaplastic oligoastrocytoma and in 
one (n=4) recurrent low-grade oli-
godendroglioma. EGFR amplifica-
tion is rare in low-grade oligo-
dendroglial tumours. Fallon et al. 
studied 138 oligodendrogliomas and 
oligoastrocytomas by FISH and 
found only one EGFR amplification 
in an anaplastic oligoastrocytoma 
(Fallon et al., 2004). In a series of 33 
oligodendrogliomas, Reifenberger et 
al. found EGFR amplification by 
Southern blotting in one case of 
anaplastic oligodendroglioma 
(Reifenberger et al., 1996). Our re-
sults are in agreement with the pre-
vious studies, although the number 
of tumours in these subgroups is 
small. Anaplastic oligodendroglial 
tumours carry EGFR amplification 
at a significantly higher rate. In a 
prospective chemotherapy study, 
EGFR amplification was present in 
18% of anaplastic oligodendroglio-
mas (Kouwenhoven et al., 2009). 
Amplification of genes on 
chromosome 4q12 (study 
III) 
PDGFRA 
In the present study PDGFRA am-
plification was found mainly in high-
grade astrocytomas. PDGFRA was 
amplified in one primary (n=35) and 
one recurrent (n=12) low-grade as-
trocytoma. Anaplastic astrocytomas 
carried PDGFRA amplification in 
33% at first diagnosis and in 12% in 
recurrent tumours. In secondary 
glioblastomas, PDGFRA amplifica-
tion was found in 31% of cases. 
PDGFRA amplification emerged in 
two tumours during progression 
from low-grade astrocytoma to 
glioblastoma (Figure 5, cases 13 and 
39). These results are well in line 
with other studies, where PDGFRA 
amplification has been found in 8-
21% of glioblastomas (Fleming et al., 
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52 
1992; Joensuu et al., 2005; Verhaak 
et al., 2010; Nobusawa et al., 2011). 
Fleming and co-workers found 
PDGFRA amplification in one of 
seven anaplastic astrocytomas by 
Southern blotting (Fleming et al., 
1992). In a recent array-CGH study, 
PDGFRA amplification was de-
tected in 13% of anaplastic astrocy-
tomas (Toedt et al., 2010). In low-
grade astrocytomas, PDGFRA am-
plification has been reported in 14-
50% of tumours by real-time quanti-
tative PCR analysis (Arjona et al., 
2005; Martinho et al., 2009). 
In the present study, oligoden-
droglial tumours did not exhibit 
PDGFRA amplification at the time 
of the diagnosis. However, at recur-
rence one anaplastic oligodendro-
glioma (n=11) and four anaplastic 
oligoastrocytomas (n=10) had ac-
quired PDGFRA amplification (Ta-
ble 5, Figure 5). Our results are in 
agreement with Martinho and co-
workers who found PDGFRA am-
plification in 1 out of 10 low-grade 
oligodendrogliomas and in 3 out of 
15 anaplastic oligodendroglial tu-
mours (Martinho et al., 2009). Smith 
et al. reported PDGFRA amplifica-
tion in 4 out of 21 anaplastic oli-
godendrogliomas and in 1 out of 11 
anaplastic oligoastrocytomas (Smith 
et al., 2000). 
In glioblastomas, PDGFRA am-
plification accumulates in a subtype 
that has a proneural gene expression 
profile (Verhaak et al., 2010). The 
proneural subtype of glioblastomas 
is characterised by genes associated 
with the progress of neurogenesis 
(Phillips et al., 2006), and it is associ-
ated with younger patient age and 
better outcome (Phillips et al., 2006; 
Verhaak et al., 2010). According to a 
recent study, activating rearrange-
ments of the PDGFRA gene are 
present in 40% of glioblastomas 
with amplified PDGFRA (Ozawa et 
al., 2010). Furthermore, Ozawa et al. 
have reported a novel gene fusion 
between PDGFRA and VEGFR2 in 
glioblastomas (Ozawa et al., 2010). 
Imatinib is a selective tyrosine 
kinase inhibitor of KIT, PDGFRs 
and BCR-ABL fusion protein, which 
is the oncogenic protein in chronic 
myelogenous leukaemia (Capdeville 
et al., 2002). Imatinib has revolution-
ized the therapy of patients with 
chronic myelogenous leukemia 
(CML) and gastrointestinal stromal 
tumor (GIST), which is characterised 
by activating mutations of KIT or 
PDGFRA (Antonescu, 2011). 
Imatinib inhibits tumour cell growth 
in primary cultures of high-grade 
gliomas (Hagerstrand et al., 2006). 
However, in a clinical trial imatinib 
therapy showed only limited efficacy 
in patients with recurrent gliomas 
(Raymond et al., 2008). 
KIT 
In the present study, KIT amplifica-
tion was found more frequently in 
recurrent tumours than in primary 
gliomas (27% vs. 10%, p<0.01). We 
found KIT amplification most fre-
quently in malignant astrocytic tu-
mours. KIT amplification was 
present in 28% of primary, in 50% 
of recurrent anaplastic astrocytomas 
and in 36% of secondary glioblas-
tomas as well. At first presentation, 
low-grade astrocytomas and oli-
godendroglial tumours carried KIT 
amplification in significantly lower 
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frequency than anaplastic astrocy-
tomas (5% vs. 28%, p=0.01). 
The frequency of KIT amplifica-
tion in a recent population-based 
study of glioblastomas was 4.4%, as 
studied by differential PCR (Nobu-
sawa et al., 2011). Holtkamp et al. 
studied 87 gliomas using the multi-
plex ligation-dependent probe ampli-
fication (MLPA) method and found 
KIT amplification in 5% of glioblas-
tomas but not in any anaplastic as-
trocytomas or oligodendrogliomas 
(Holtkamp et al., 2007). The differ-
ences in KIT amplification fre-
quency between the studies may be 
due to different detection methods 
and patient material. 
Nobusawa and co-workers did 
not detect a significant difference in 
KIT amplification frequency be-
tween primary and secondary 
glioblastomas (Nobusawa et al., 
2011). This result suggests that KIT 
amplification may be involved in the 
pathogenesis of both primary and 
secondary glioblastomas. Notably, in 
our material, 5 of 13 astrocytomas 
acquired KIT amplification during 
progression from grade II to III, 
suggesting that KIT may play a role 
in the progression of low-grade as-
trocytomas as well. 
Mutations of KIT have not been 
reported in gliomas. Joensuu and co-
workers did not detect any KIT mu-
tations in a series of 47 glioblas-
tomas (Joensuu et al., 2005). At 
protein level, KIT expression was 
rare in our material; moderate or 
strong immunoreactivity was present 
in only two anaplastic astrocytomas 
and two secondary glioblastomas. All 
four tumours that expressed KIT by 
immunohistochemistry harboured 
KIT amplification. 
VEGFR2 
In the present study, VEGFR2 
amplification was found in 5 (14%) 
low-grade astrocytomas, in 3 (17%) 
anaplastic astrocytomas and in 2 
(11%) oligodendroglial tumours at 
first diagnosis. There was no signifi-
cant difference in the VEGFR2 am-
plification rate between primary and 
recurrent gliomas (12% vs. 14%). 
Two (12%) secondary glioblastomas 
harboured VEGFR2 amplification. 
In their population-based study of 
glioblastomas, Nobusawa et al. de-
tected VEGFR2 amplification in 
3.3% of tumours (Nobusawa et al., 
2011). Holtkamp and co-workers did 
not find VEGFR2 amplifications in 
a series of 10 anaplastic astrocy-
tomas and 12 oligodendrogliomas 
(Holtkamp et al., 2007). 
We found immunohistochemical 
VEGFR2 expression in 28 of 51 
(47%) of astrocytic tumours at first 
diagnosis. Oligodendroglial tumours 
were negative by VEGFR2 immu-
nohistochemistry at first diagnosis. 
In our material, VEGFR2 expression 
did not correlate with VEGFR2 am-
plification. Steiner and co-workers 
have demonstrated coexpression of 
VEGF and its receptor VEGFR2 in 
glioblastomas, suggesting a presence 
of an autocrine signalling loop 
(Steiner et al., 2004). VEGFR2 ex-
pression has been detected in 
glioblastoma cell lines as well (Holt-
kamp et al., 2007). VEGF upregula-
tion and simultaneous amplification 
of its receptor VEGFR2 in gliomas 
cells may facilitate tumour growth. 
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Co-amplification of KIT, 
PDGFRA and VEGFR2 
We found co-amplification of KIT, 
PDGFRA and VEGFR2, which are 
located at 4q12, in 2 primary 
anaplastic astrocytomas (3% of in-
formative primary tumours, Figure 
5). At recurrence, co-amplification of 
the three genes was present in 5 
(7%) tumours (1 astrocytoma grade 
III, 1 glioblastoma, 1 oligodendro-
glioma grade III and 2 oligoastrocy-
tomas grade III). In a recent series of 
glioblastomas, co-amplification of 
the three genes was present in 3.1% 
of tumours (Nobusawa et al., 2011). 
Prognostic value of KIT, 
PDGFRA and EGFR 
amplifications 
In our study, PDGFRA (p=0.047), 
KIT (p=0.015) and EGFR 
(p=0.0003) amplifications were 
prognostic factors for overall sur-
vival in univariate analysis. However, 
in multivariate analysis that included 
tumour histology and grade, the 
gene amplifications were not associ-
ated with prognosis. This result is 
probably due to the fact that ampli-
fication of PDGFRA (p=0.014) and 
EGFR (p=0.048) were associated 
with tumour grade in primary tu-
mours. Järvelä and co-workers re-
ported a negative association 
between EGFR amplification and 
survival in anaplastic astrocytomas 
(Järvelä et al., 2006) but two other 
studies found no such association 
(Smith et al., 2001; Liu et al., 2005). 
In glioblastomas, EGFR amplifica-
tion is not an independent prognos-
tic factor (Liu et al., 2005; Järvelä et 
al., 2006) with an exception of pa-
tients over 60 years of age (Smith et 
al., 2001). 
Mutations of p53 gene 
We detected p53 gene mutations at 
first diagnosis in 11 (29%) low-grade 
astrocytomas, in 5 (28%) anaplastic 
astrocytomas and in 7 (22%) oli-
godendroglial tumours. There was 
no significant difference in the fre-
quency of p53 mutations between 
first diagnosis and recurrence, indi-
cating that the p53 mutation is an 
early event in the progression of 
gliomas. In a population-based study 
of low-grade gliomas, p53 mutations 
were present in 59% of astrocytomas 
and in 23% of oligodendroglial tu-
mours (Okamoto et al., 2004). The 
lower frequency of p53 mutations 
detected in our material may be due 
to different patient population and 
detection methods. p53 mutation is a 
genetic hallmark of secondary 
glioblastomas (Ohgaki and Kleihues, 
2007). In our material, 6 (38%) sec-
ondary glioblastomas harboured p53 
mutation. 
Expression of COX-2 and 
HuR in gliomas (study IV) 
COX-2 
We studied COX-2 expression in 
primary and recurrent gliomas of 
113 patients. Histological diagnoses 
and WHO grade of the tumours are 
shown in Table 6. We found a high 
level of COX-2 expression in 65 
(28%) of gliomas (Table 6). COX-2 
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expression was observed in all sub-
types of diffuse gliomas. There was 
no significant difference in COX-2 
immunostaining between astrocy-
tomas, oligodendrogliomas and oli-
goastrocytomas. Upregulated COX-
2 expression was associated with 
higher WHO grade (p<0.001) in the 
whole tumour group and in sub-
groups of astrocytomas (p<0.001) 
and oligodendrogliomas (p<0.001). 
Our results are in accordance with 
previous studies, where COX-2 im-
munoexpression correlated posi-
tively with tumour grade in 
astrocytomas (Joki et al., 2000; 
Shono et al., 2001; Hara and Oka-
yasu, 2004). Similarly, Castilla and 
co-workers found elevated COX-2 
expression in high-grade oligoden-
drogliomas (Castilla et al., 2003). 
HuR 
We detected nuclear expression of 
HuR in all studied tumours. The 
nuclei of neurons that were inside 
the infiltrating glioma tissue were 
positive by immunohistochemistry 
as well. Cytoplasmic HuR immuno-
reactivity was present in 44 gliomas 
(20%, Table 6). We analysed cyto-
plasmic HuR expression because the 
shuttling of HuR between nucleus 
and cytoplasm is considered the 
main mechanism of its mRNA stabi-
lisation activity (Doller et al., 2008). 
Furthermore, elevated cytoplasmic 
HuR content is linked to patient 
outcome in breast carcinoma and 
ovarian carcinoma (Erkinheimo et 
al., 2003; Heinonen et al., 2005). The 
immunohistochemical method is 
suitable for analysing HuR expres-
sion in brain tumours because it en-
ables the study of subcellular local-
ization of the protein. 
Few reports have been published 
on the role of HuR in brain tumours. 
Nabors et al. observed HuR expres-
sion at the mRNA level in glioblas-
tomas, pilocytic astrocytomas, 
ependymomas, medulloblastomas 
and meningiomas (Nabors et al., 
2001). In their material, immunohis-
tochemistry revealed a predomi-
nantly nuclear staining pattern with 
weak cytoplasmic staining in 
glioblastomas (Nabors et al., 2001). 
In another a series of 27 astrocy-
tomas, HuR mRNA expression and 
nuclear immunoreactivity were 
found in all tumours (Ido et al., 
2008). Cytoplasmic immunoreactiv-
ity was associated with higher tu-
mour grade (Ido et al., 2008).  
In the present study, cytoplasmic 
HuR expression correlated with 
higher tumour grade in the whole 
material (p<0.001) and in astrocy-
tomas (p<0.001) but not in oli-
godendrogliomas or oligo-
astrocytomas. Thus, our results 
suggest that cytoplasmic localization 
of HuR could be involved in glioma 
progression. However, no significant 
association was observed between 
histological glioma type and cyto-
plasmic HuR staining indicating that 
upregulation of HuR may play a role 
in the pathogenesis of both astrocy-
tomas and oligodendrogliomas. A 
significant difference was seen in 
cytoplasmic HuR expression be-
tween primary and secondary 
glioblastomas in the recurrent tu-
mour group (p=0.01, Table 6), 
which reflects divergent pathogene-
sis of these tumours. 
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Association of COX-2 and 
HuR expression in 
gliomas (study IV) 
We found a significant correlation 
between cytoplasmic HuR staining 
and a high level of COX-2 expres-
sion (p<0.001). A similar association 
between HuR and COX-2 has been 
observed in carcinomas of the 
breast, ovary, colon and stomach 
(Erkinheimo et al., 2003; Denkert et 
al., 2004b; Mrena et al., 2005; Den-
kert et al., 2006). Experimental stud-
ies have shown that HuR regulates 
COX-2 mRNA and protein expres-
sion in cell lines (Dixon et al., 2001; 
Sengupta et al., 2003; Mrena et al., 
2005; Young et al., 2009). Moreover, 
HuR is involved in the stabilisation 
of mRNAs of many other genes re-
lated to cancer, such as cyclins, HIF-
1α and VEGF (Lopez de Silanes et 
al., 2005). There is evidence that 
HuR regulates the expression of 
VEGF in gliomas as well. Ido and 
co-workers have shown that the in-
hibition of cytoplasmic translocation 
of HuR reduces VEGF expression 
astrocytoma cell lines (Ido et al., 
2008). Despite the substantial evi-
dence that links HuR and cancer, it 
is still not known if HuR has a causal 
role in tumourigenesis. 
Prognostic value of COX-
2 and HuR in gliomas 
(study IV) 
In the present study, univariate sur-
vival analysis showed a significant 
correlation between overall survival 
and histological tumour type 
(p<0.001), WHO grade (p<0.001), 
age at diagnosis (p=0.02), cytoplas-
mic HuR expression (p<0.001), high 
COX-2 expression (p=0.001) and 
combination of HuR/COX-2 ex-
pression (p<0.001). Next, we per-
formed multivariate survival analysis 
to evaluate the independence of 
HuR and COX-2 as prognostic fac-
tors. In Cox multivariate analysis, 
histological tumour type (p<0.001), 
WHO grade (p<0.001) and patient 
age (p=0.03) were independent 
prognostic markers for overall sur-
vival. Expression of HuR and COX-
2 were not independently associated 
with patient outcome probably due 
to their strong association with 
WHO grade. In a previous study, 
COX-2 was associated with poor 
patient outcome independent of tu-
mour grade in astrocytomas (Shono 
et al., 2001). However, in the mate-
rial by Shono and co-workers, WHO 
grade was not associated with prog-
nosis, which is contrary to current 
knowledge (Louis et al., 2007). The 
correlation between COX-2 expres-
sion and prognosis has been ob-
served in astrocytomas (Hara and 
Okayasu, 2004) and in oligodendro-
gliomas (Castilla et al., 2003) in uni-
variate survival analysis. Cytoplasmic 
HuR expression is a prognostic 
marker in carcinomas of the breast 
and ovary (Erkinheimo et al., 2003; 
Denkert et al., 2004a; Heinonen et 
al., 2005). The role of HuR as a 
prognostic factor in gliomas has not 
been reported previously. 
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Molecular changes during 
glioma progression 
(studies II-IV) 
Results of the current study show 
that the immunohistochemically de-
tected expression of ezrin (p<0.05) 
and COX-2 (p<0.001) increased 
significantly between the first and 
second glioma operation. However, 
no significant difference was seen in 
the cytoplasmic expression of HuR 
between gliomas at first diagnosis 
and recurrence. At DNA level, am-
plification of the KIT gene was pre-
sent more frequently in recurrent 
gliomas compared to their primary 
tumours (p<0.05). Amplification 
frequencies of PDGFRA, VEGFR2 
and EGFR were not significantly 
different between primary and recur-
rent gliomas, but the number of tu-
mours with these alterations was 
small. 
Progression of gliomas from low-
grade to high-grade tumours is char-
acterised by the sequential accumula-
tion of genetic alterations, epigenetic 
changes and dysregulation of pro-
teins related to cell proliferation. 
These changes may be directly in-
volved in tumourigenesis or they 
may reflect secondary alterations due 
to dysfunction of common path-
ways. Previous studies have identi-
fied several genetic alterations that 
are present in recurrent gliomas but 
not in the corresponding primary 
tumours. Deletion of the tumour 
suppressor gene CDKN2A is in-
volved in the development of tu-
mour recurrences in both 
astrocytomas and oligodendroglio-
mas (Hulsebos et al., 1998; Jeuken et 
al., 2002; Idbaih et al., 2008; Jeuken 
et al., 2010). Other tumour suppres-
sor genes that are implicated in 
glioma progression include Rb1 
(Hulsebos et al., 1998) and PTEN 
(Jeuken et al., 2010). According to 
recent literature, MGMT promoter 
methylation status may change from 
unmethylated to methylated during 
progression of oligodendrogliomas 
(Lavon et al., 2007) and in glioblas-
tomas after the initial diagnosis 
(Brandes et al., 2010; Jung et al., 
2010). 
At present, it is not known if the 
alterations we detected in the ex-
pression of ezrin and COX-2 and if 
the amplification of the KIT gene 
are directly linked to the tumouri-
genesis of gliomas. It is possible that 
they merely represent dysregulation 
of the glioma cell proteome and ge-
nomic instability. However, these 
alterations could be used as surro-
gate markers of glioma progression 
together with other genetic and epi-
genetic aberrations of gliomas. Cur-
rently, the state-of-the-art molecular 
markers that are used in diagnostic 
and prognostic assessment of glio-
mas include 1p/19q deletions, 
MGMT promoter methylation, 
IDH1 mutation and EGFR amplifi-
cation as reviewed above. 
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CONCLUDING REMARKS 
In the first part of this thesis, we 
focused on the correlation of con-
trast enhancement in MRI and im-
munohistochemical analysis of 
gliomas. Based on our results, pre-
operative MRI may be used to esti-
mate tumour cell proliferation 
activity and vascular density in grade 
II-IV diffuse gliomas. This informa-
tion is of clinical value because the 
tissue sample submitted for histopa-
thological analysis may not represent 
the most proliferative part of the 
tumour, whereas by MRI the tumour 
can be evaluated as a whole. How-
ever, contrast enhancement should 
be evaluated cautiously together with 
clinical information and other MRI 
features to exclude pilocytic astrocy-
tomas and other enhancing brain 
lesions. 
Secondly, we studied gene ampli-
fications and proteins related to the 
recurrence and progression of glio-
mas. We confirmed that ezrin is ex-
pressed at protein level in both 
astrocytomas and oligodendroglio-
mas, and ezrin may play a role in the 
progression of these tumours. High 
ezrin expression correlates with poor 
patient outcome although it is not an 
independent prognostic factor. 
Amplifications of PDGFRA, 
KIT and VEGFR2 are present in 
both low-grade and malignant glio-
mas. PDGFRA and KIT amplifica-
tions occur most frequently in high-
grade astrocytomas and in secondary 
glioblastomas. Since the frequency 
of KIT amplification increases in 
recurrent gliomas, KIT appears to be 
linked to tumour progression. 
We found that COX-2 expres-
sion is upregulated in gliomas in a 
grade dependent manner. Cytoplas-
mic HuR expression correlates with 
COX-2 expression in gliomas. 
Therefore, HuR is a potential regula-
tor of COX-2 in gliomas, as in many 
epithelial cancers. Expression of 
COX-2 and HuR are prognostic fac-
tors for glioma patient survival in 
univariate analysis but not in multi-
variate analysis. 
The strength of this study is the 
long follow-up time of the patients 
(median of 10 years for low-grade 
gliomas). A follow-up of several 
years is essential, because the median 
survival time of patients with low-
grade gliomas is over 7 years (Oka-
moto et al., 2004). There are two 
limitations in this study. First, the 
tumour material was collected retro-
spectively. Second, we included only 
tumour pairs from primary and re-
current glioma operations. This ap-
proach may cause selection bias to 
the results. We used multivariate 
analysis to control the effects of pa-
tient age, histological type and grade 
that are known to have a strong as-
sociation with the recurrence and 
malignancy of gliomas. Despite these 
limitations, our results give some 
new insights into the progression of 
gliomas. 
The main future targets in the 
treatment of gliomas are the elimina-
tion of glioma stem cells and migrat-
ing tumour cells, which are 
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eventually fatal to the patient. 
Glioma stem cells maintain the tu-
mour cell proliferation and growth 
but they are resistant to current 
therapies. Development of new 
treatments also requires novel imag-
ing tools capable of monitoring 
glioma stem cells and dissemination 
of tumour cells. 
Management of patients with 
low-grade diffuse gliomas is a chal-
lenge to a neuro-oncological team. 
The patients undergo several recur-
rences and treatment modalities dur-
ing the course of the disease that 
may span over 10 years. Continuing 
research of the molecular biology of 
gliomas is needed to find markers 
that would identify patients at risk 
for early malignant transformation 
and to reveal possible targets for 
therapeutic interventions. These 
markers and new treatment strate-
gies should be validated in prospec-
tive trials to determine optimal 
management strategies for glioma 
patients. 
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